<<<<<<< HEAD
element_id,text,page_number,filename,chunk_id,relevant
26e2ffa12765874ed647b25892f5742c,Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease,1,ALD patent background + target paper.pdf,2,True
a97990c757688b2ad9f9547223e628af,"Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol- induced liver disease in mice4, but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin—a two-subunit exotoxin that is secreted by Enterococcus faecalis5,6—as a cause of hepatocyte death",1,ALD patent background + target paper.pdf,7,True
7700e213119d995bb900c028b2058ba8,"and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of",1,ALD patent background + target paper.pdf,8,True
55628f8d8fcd11065a2f49008a2a0a12,"bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort",1,ALD patent background + target paper.pdf,9,True
4d0808dcc0de15622ab920197f3e824e,"The most severe form of alcohol-related liver disease is alcoholic hepa- titis; mortality ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a diagnosis of severe alcoholic hepatitis7–9. Therapy with corticosteroids is only marginally effective9. Early liver transplantation is the only curative therapy, but is offered only at select centres and to a limited group of patients10.",1,ALD patent background + target paper.pdf,11,True
06eaaa92b96ca86c0147a2adb438eadb,Alcohol-related liver disease can be transmitted via faecal micro- biota4. We investigated the microorganisms and microbial factors that are responsible for this transmissible phenotype and for progression of alcohol-related liver disease.,1,ALD patent background + target paper.pdf,12,True
7d4f7d11058fefb73c25d74168a266b2,"with an altered composition of the faecal microbiota. Differences in faecal microbiota composition were noted in patients with alcohol-use disorder and alcoholic hepatitis, compared to subjects without alcohol- use disorder (controls) (Fig. 1a, Extended Data Fig. 1a, b, Supplementary Tables 1, 2). One substantial difference that we observed was an increase in the proportion of Enterococcus spp. in patients with alcoholic hepa- titis: in these patients, 5.59% of faecal bacteria were Enterococcus",1,ALD patent background + target paper.pdf,16,True
5d8c1ebe16d59c1d317dffc791695a29,"spp. compared with almost none in controls (0.023%; for comparison, 0.004% of all reads were Enterococcus spp. in the Human Microbiome Project) or patients with alcohol-use disorder (0.024%). Faecal sam- ples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls, as measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), which is consistent with the 16S rRNA sequencing results. About 80% of patients with alcoholic hepatitis are positive for",1,ALD patent background + target paper.pdf,17,True
2a0fa3f8a748f185786faa503f15c12e,"with faecal samples that were positive for both cylLL and cylLS DNA sequences (cytolysin-positive), in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. Statistically significant differences were detected between controls and patients with alcoholic hepatitis (P < 0.01), and between patients with alcohol- use disorder and patients with alcoholic hepatitis (P < 0.001). c, Kaplan–Meier curve of survival of patients with alcoholic",2,ALD patent background + target paper.pdf,30,True
c0cb33fc914a181a931f63d3f064994f,"hepatitis whose faecal samples were cytolysin-positive (n = 25) or cytolysin-negative (n = 54) (P < 0.0001). d, Core genome single-nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis (n = 93 strains, from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. faecalis. Genomically identical isolates from the same patient were combined, and are shown as a single dot. Scale bar represents the nucleotide substitutions per",2,ALD patent background + target paper.pdf,31,True
5f83e60c4dddb2f0280d1a7e278bce89,"SNP site. P values are determined by permutational multivariate analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR procedures (b) or two-sided log- rank (Mantel–Cox) test (c). The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",2,ALD patent background + target paper.pdf,32,True
561904fc909fe66441a85e2fd6b522a7,"The colonization of mice with E. faecalis induces mild hepatic stea- tosis and exacerbates ethanol-induced liver disease11, by mechanisms that are unclear. Cytolysin is a bacterial exotoxin (or bacteriocin) that is produced by E. faecalis12, and which contains two post-translationally modified peptides (CylLL′′ and CylLS′′) in its bioactive form6. The two peptides are encoded by two separate genes: cylLL and cylLS, respec- tively12. Cytolysin has lytic activity against not only Gram-positive",2,ALD patent background + target paper.pdf,33,True
611eb13b2d6e50c5fddc28b53f5e5681,"bacte- ria, but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA (cytolysin-positive) in faecal samples from 30% of patients with alco- holic hepatitis; none of the faecal samples from controls and only one sample from a patient with alcohol-use disorder was cytolysin-positive, as detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-positive patients with alcoholic hepatitis died within 180 days of admission, compared to only 3.8% of cytolysin-negative patients (P < 0.0001)",2,ALD patent background + target paper.pdf,34,True
143566463ffffbf593619724e143bd32,"(Fig. 1c). Among the cytolysin-positive patients, 72.2% (13 out of 18) died owing to liver failure (including complications related to liver",2,ALD patent background + target paper.pdf,35,True
caa8512566105619e699d5975503c375,"failure, such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not associated with 30-day, 90-day or 180-day mortality (P = 0.403, 0.234 or 0.098) in patients with alcoholic hepatitis.",2,ALD patent background + target paper.pdf,37,True
79535293be1afc815d786a3f02a7f4b1,"Our univariate logistic and Cox regression of laboratory and clinical parameters found an association between the detection of cytolysin- encoding genes in faeces and the international normalized ratio (INR), platelet count, the model for end-stage liver disease (MELD) score, the sodium MELD score, the age, serum bilirubin, INR and serum creatinine (ABIC) score and death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding genes in faeces was associated with",2,ALD patent background + target paper.pdf,38,True
e6d629f4b1c9cb4dc395249f617132df,"90-day (P = 0.004) and with 180-day mortality (P = 0.001) (Supple- mentary Table 3), even after we adjusted for the geographical origin of the patient, antibiotic treatment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. We found no multicollinear- ity between the detection of faecal cytolysin-encoding genes and these cofactors (variance inflation factor < 1.6), which indicates that cytolysin is an independent predictor of mortality in patients with alcoholic",2,ALD patent background + target paper.pdf,39,True
94cde9ce9ef95ccd106fb02ae05cfb3e,"hepatitis. When we performed receiver-operating-characteristic curve analysis for 90-day mortality, cytolysin had an area under the curve of 0.81, which was superior to other widely used predictors for mortality in clinical practice (Extended Data Fig. 1e). On the basis of our findings, we propose that the detection of cytolysin may be a prognostic factor for more severe liver- related outcomes and increased risk of death, and a stronger predictor of mortality than MELD, ABIC and the",2,ALD patent background + target paper.pdf,40,True
902cf4996a4515d0de2f125dc02eddb3,"To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed targeted culturing from stool samples. Whole- genome sequencing of 93 E. faecalis isolates revealed a broad phylo- genetic diversity of cytolysin-positive E. faecalis from patients with alcoholic hepatitis (Fig. 1d), which indicates that cytolysin production is a variable trait among E. faecalis isolates and that cytolysin is car- ried in mobile genetic elements, which include both chromosomally encoded",2,ALD patent background + target paper.pdf,42,True
ebbb35022ddcef9c9c90ac7e6187c74d,pathogenicity islands and plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Table 4).,2,ALD patent background + target paper.pdf,43,True
4715251334e04eee26610aa45866c63d,"The total amount of faecal E. faecalis, or faecal E. faecalis positivity, did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5, 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar amounts of faecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the composition of the gut microbiota in patients with alcoholic hepatitis from different geographical regions (Extended Data",2,ALD patent background + target paper.pdf,44,True
f6ecdb28a54e5d4d94f4a14a103736db,"Fig. 1g), the proportion of cytolysin-positive patients, total amount of faecal E. faecalis, faecal E. faecalis positivity (Extended Data Fig. 1h–j), treatment and clinical outcomes (30-day and 90-day mortality) did not differ significantly among the regions or centres (Supplemen- tary Table 7). In addition, cirrhosis was not associated with cytolysin positivity, the total amount of faecal E. faecalis or faecal E. faecalis positivity in patients with alcoholic hepatitis (Extended Data Fig. 1k–m,",2,ALD patent background + target paper.pdf,45,True
e6db8bdc4405a6e2124134e9bb1b881b,Supplementary Tables 4–6). These results confirm our findings that the presence of cytolysin-producing E. faecalis rather than the total amount or presence of E. faecalis per se determines the severity of alcoholic hepatitis and mortality.,2,ALD patent background + target paper.pdf,46,True
4394ea43077688af40457154fcf3fe86,"To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we gavaged mice with a cytolytic E. faecalis strain (FA2- 2(pAM714)) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol diet15. Compared to mice gavaged with phosphate-buffered saline (PBS), mice fed with ethanol after they were gavaged with cytolytic E. faecalis developed more severe liver injury as indicated by a higher level of alanine amino-",2,ALD patent background + target paper.pdf,48,True
803be30d6b7b9beb9e0d255c9c9300e4,"groups, right), and incubated with vehicle, CylLS′′, CylLL′′ or both of the cytolysin subunits at the indicated concentrations without (–) or with (+) ethanol (25 mM) for 3 h. The survival of hepatocytes was determined in three independent experiments. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h). P values are determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures (g) or",3,ALD patent background + target paper.pdf,71,True
fd3e1df3ce5c323b45e75f5eaef59c84,"two-way ANOVA with Tukey’s post hoc test (h). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",3,ALD patent background + target paper.pdf,72,True
c721bc91a482f5706172d5baa91a3482,"were gavaged with cytolytic E. faecalis also had more liver inflamma- tion with higher expression levels of mRNAs that encode inflamma- tory cytokines and chemokines (Il1b, Cxcl1 and Cxcl2) (Extended Data Fig. 2d–f), compared with mice given PBS. Mice that were fed ethanol after they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver injury, steatosis and inflammation (Extended Data Fig. 2a–f) and longer survival times (Extended Data Fig. 2g), as compared",3,ALD patent background + target paper.pdf,73,True
549e1cb07f3051eab773a26b636ae6b4,"To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in the liver. CylLS was significantly increased in the liver of mice given cytolytic E. faecalis but not in the liver of mice that were not given E. faecalis or of mice gavaged with non-cyto- lytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable in the liver of mice given cytolytic and",3,ALD patent background + target paper.pdf,75,True
b475e1e40238cbba321930bb216f97e5,"non-cytolytic E. faecalis and fed an ethanol diet, but not when mice were fed an isocaloric (control) diet (Extended Data Fig. 2i); this indicates that ethanol-induced changes in the gut barrier are necessary for the translocation of cytolytic E. faecalis from the intestine to the liver. The livers of ethanol-fed mice that were given cytolytic or non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed an increased intestinal permeability in ethanol-fed",3,ALD patent background + target paper.pdf,76,True
c1a4bb6c553d4c3522586bf5dca2d7c3,"Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change the composition of the intestinal microbiota, as shown by 16S rRNA gene sequencing (Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic metabolism",3,ALD patent background + target paper.pdf,78,True
087245f4a6bfbf0ce492cdb0a56d81d7,"chronic–binge feeding model, gavaged with control phages against C. crescentus (1010 plaque-forming units (PFUs)) or a cocktail of three or four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT.",4,ALD patent background + target paper.pdf,102,True
d253e3a43ab52f08a6245d521ebcb8d0,"of ethanol, as indicated by serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs (which encode the two primary enzymes that metabolize ethanol in the liver) (Extended Data Fig. 2m, n). These results indicate that E. faecalis that produce cytolysin promote ethanol- induced liver disease in mice.",4,ALD patent background + target paper.pdf,105,True
ffdc6a9c01768b9a6dedf3176294f83d,"To extend our findings to humans, we colonized germ-free mice with faeces from cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobi- otic C57BL/6 mice colonized with faeces from two cytolysin-positive patients developed more severe ethanol-induced liver injury, steatosis, inflammation and fibrosis than mice given faeces from two cytolysin- negative patients (Fig.",4,ALD patent background + target paper.pdf,106,True
3575029f1aaf0a5f7162ca210a4d3957,"cytolytic E. faecalis to the liver after ethanol administration (Fig. 2g). The overall composition of the intestinal microbiota was not differ- ent between mice fed the control diet and colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, as shown by 16S rRNA gene sequencing. Mice transplanted with faeces from one of the cytolysin-positive patients with alcoholic hepatitis (patient no. 2) showed a microbiota that was significantly different from",4,ALD patent background + target paper.pdf,109,True
6e607ff4fcf96493e90864e165d30e92,"that of the other mouse groups after ethanol administration (Extended Data Fig. 3f). Non-cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorp- tion or hepatic metabolism of ethanol between mice colonized with faeces from cytolysin-positive versus cytolysin-negative patients (Extended Data Fig. 3h, i). Together, these results provide further evi- dence that cytolysin promotes",4,ALD patent background + target paper.pdf,110,True
f4e427a72049170a6628d99269b98ce6,"To determine the mechanism by which cytolysin increases liver dis- ease, we isolated hepatocytes from mice fed ethanol or control diets, and stimulated them with pure bioactive cytolysin peptides (CylLL′′ and CylLS′′)6. Incubation of the primary mouse hepatocytes with the two cytolysin subunits caused a dose-dependent increase in cell death compared to hepatocytes that were incubated with vehicle or with one subunit only (Fig. 2h). When we isolated hepatocytes from ethanol-fed mice and then",5,ALD patent background + target paper.pdf,140,True
214ae1e568b34b33b939e97c1f233f1c,"incubated these hepatocytes with ethanol, we did not observe increased levels of cytolysin-induced cell death compared to hepatocytes isolated from mice on the control diet, which indicates that cytolysin-induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are possibly mediated by pore forma- tion, resulting in cell lysis14.",5,ALD patent background + target paper.pdf,141,True
20fc8211be2207f7ebbc1f9da4b90d6b,"we investigated the effects of treatment with bacteriophages (here- after, phages). Phages are ubiquitous in bacteria-rich environments, including the gut16. E. faecalis phages that are highly strain-specific can be isolated17, which potentially makes the direct editing of gut microbiota feasible. It has previously been shown that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, which is associated with increased susceptibility to alcohol-induced",5,ALD patent background + target paper.pdf,146,True
f783833317fcda1d67fae16824103ca1,steatohepatitis11. The gavaging of wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice led to increased ethanol-induced steatohepatitis11. We found that this same E. faecalis strain expressed cytolysin. We then isolated four distinct phages from sewage water. These phages lyse the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type littermates,5,ALD patent background + target paper.pdf,147,True
d9ac1b615fdd2bf5e600d7df13fec8de,"Compared to Atp4aSl/Sl mice gavaged with control phages or vehicle, Atp4aSl/Sl mice gavaged with phages that target cytolytic E. faecalis had less severe liver injury, steatosis and inflammation after chronic ethanol feeding (Extended Data Fig. 5a–f). Administration of E. faecalis phages significantly reduced levels of cytolysin in the liver (Extended Data Fig. 5g) as well as faecal amounts of Enterococcus (Extended Data Fig. 5h). Phage administration did not affect the overall composition of",6,ALD patent background + target paper.pdf,151,True
fcaf8ee93aa30caad09e40b224cb1dc1,"To develop a therapeutic approach to precisely edit the intestinal microbiota, we cultured cytolytic E. faecalis strains from the faecal samples of patients with alcoholic hepatitis. We then isolated lytic phages from sewage water against these cytolytic E. faecalis strains; these phages had siphophage or myophage morphology (Fig. 3a, Extended Data Fig. 6). Gnotobiotic mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (Sup- plementary Table 8) and",6,ALD patent background + target paper.pdf,153,True
baf51e181775b4dcfa74544228c84273,"given three or four different—but patient- specific—lytic phages against cytolytic E. faecalis. The phages against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, as shown by lower levels of ALT, lower percentages of hepatic cells positive for terminal deoxynucleotide transferase-mediated dUTP nick-end labelling, and lower levels of hepatic triglycerides and oil red O-staining (Fig. 3b–d, Extended Data Fig. 7a, b), as well as by decreased hepatic levels of Il1b,",6,ALD patent background + target paper.pdf,154,True
10f2c121251e7865f10e7f5043ac0bc3,"Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLS, as compared with mice given control phages (against C. crescentus) (Fig. 3e–h, Extended Data Fig. 7c, d). Treatment with phages against cytolytic E. faecalis also reduced faecal amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were similar in all groups (Extended Data Fig. 7g, h).",6,ALD patent background + target paper.pdf,155,True
da9fd7f19241044c965123053eb42f33,"To demonstrate that the effect of phage treatment occurs via the targeting of cytolysin-positive E. faecalis, rather than a reduction in cytolysin-negative E. faecalis, we colonized gnotobiotic mice with faeces from cytolysin-negative patients with alcoholic hepatitis (Sup- plementary Table 8). Phages against non-cytolytic E. faecalis from patients were isolated from sewage water; they had siphophage or podophage morphology (Fig. 4a, Extended Data Fig. 8). These phages did not reduce features of",6,ALD patent background + target paper.pdf,156,True
60dd9e4ba9b6783c14557df1602b62e3,"ethanol-induced liver disease compared with control phages (Fig. 4b–g, Extended Data Fig. 9a–h), despite the reduc- tion of faecal Enterococcus (Fig. 4h). Our findings indicate that treat- ment with lytic phages can selectively attenuate the ethanol-induced liver disease caused by cytolysin-positive E. faecalis in humanized mice.",6,ALD patent background + target paper.pdf,157,True
498f1d8b3a437ae999e672b742edacb6,"Phage-based therapies have predominantly been studied in patients with bacterial infections in the gastrointestinal tract21–23, urinary tract24,25 and other organ systems26–28. The results of these studies— although mixed in terms of efficacy—strongly suggest that phage treat- ment offers a safe alternative to antibiotics26,27. However, safety studies are required for complex populations (such as patients with alcoholic hepatitis), because phages can induce a strong immune reaction29. Further",6,ALD patent background + target paper.pdf,159,True
a7f4dd56d870f83786e1ded97b09e6de,"work is required to determine whether phages that target cyto- lytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening disease that at present has no effective treatment. Eradication of this specific bacterial strain might produce better out- comes than current treatments, and environmental sources can be used to easily isolate phages that target cytolysin-positive E. faecalis. Here we provide an example of the efficacy of approaches based on phages in mice",6,ALD patent background + target paper.pdf,160,True
c04244d11660c52310810cb9c64c925b,"for a disease that is not considered a classic infectious disease. Our data also suggest that cytolysin may be used as a predictive biomarker of severe alcoholic hepatitis; an independent, prospective",6,ALD patent background + target paper.pdf,161,True
dc5e40d76e0eab42204f6a8153750a98,"7. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193–199 (1978).

8. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747–2756 (2008).

9. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).

10. Mathurin, P. & Lucey, M. R. Management of alcoholic hepatitis. J. Hepatol. 56, S39–S45 (2012).",6,ALD patent background + target paper.pdf,170,True
6ab480a65fa21c7c89c54c7f244a5b0c,"11. Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).",6,ALD patent background + target paper.pdf,171,True
58b63f2ac1b1120161190d90537f9369,No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.,8,ALD patent background + target paper.pdf,194,True
e042944def6cf71eb330b21b17b93bb3,"26 subjects without alcohol-use disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol-use disorder and 88 patients with alcoholic hepatitis. Patients with alcohol-use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption (self-reported >60 g/day) presented with various stages of liver disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index) (Supplementary Table 1). Patients with alcohol-use disorder",8,ALD patent background + target paper.pdf,196,True
c0ca7b327033c0e6165379376b8c68ba,"were recruited from an alcohol withdrawal unit in San Diego and Brussels, where they followed a detoxification and rehabilitation programme. At admission to the hospital, a complete medication and medical history was taken, and a complete physical examination was performed, including collection of bio-specimens, basic demographic data (such as age, gender, weight and height) and self-reported daily alcohol consumption. Patients were actively drink- ing until the day of admission. Controls or",8,ALD patent background + target paper.pdf,197,True
0f976c0e660004200f04da06431ab779,"Spain. Inclusion criteria for this study were active alcohol abuse (>50 g/day for men and >40 g/day for women) in the past 3 months, aspartate aminotransferase (AST) > ALT and total bilirubin >3 mg/dl in the past 3 months, and a liver biopsy and/or clinical picture consistent with alco- holic hepatitis. Exclusion criteria were autoimmune liver disease (ANA >1/320), chronic viral hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, pregnancy and a",8,ALD patent background + target paper.pdf,199,True
cd245ece245b24fa43712674060a852e,"lack of signed informed consent. In all patients, the clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology was consistent with the diagnosis of alco- holic hepatitis. Liver biopsies were only done if clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic hepatitis. Bio-specimens were collected during their admission to the hospital. The median time of specimen collection was 4 days fol- lowing",8,ALD patent background + target paper.pdf,200,True
38ce4f336a6096a4e0eb4efc385c6884,"admission to the hospital (range 0–24, n = 82). For one patient who underwent liver transplantation, the transplantation date was considered as date of death. Patients were censored at the time point at which they were last seen alive. The baseline characteristics are shown in Supplementary Tables 1, 2. Faecal 16S rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, ABIC score and discriminant function were calculated from all alcoholic hepatitis patients from whom",8,ALD patent background + target paper.pdf,201,True
8c2cd087d7482ec1cc860453e9de31fb,"Mice

C57BL/6 mice were purchased from Charles River and used in Fig. 2h and Extended Data Fig. 2. C57BL/6 germ-free mice were bred at UCSD and used in Figs. 2a–g, 3, 4, Extended Data Figs. 3, 7 and 9. Sublytic Atp4aSl/Sl",8,ALD patent background + target paper.pdf,204,True
0acac659a7a3f3c83930f1adf07c902d,"mice on a C57BL/6 background have previously been described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their wild-type littermates were used in Extended Data Fig. 5.",8,ALD patent background + target paper.pdf,206,True
db0feac9cc609c82c55d0c628caf10f8,"Female and male mice (age of 9–12 weeks) were placed on a chronic– binge ethanol diet (NIAAA model) as previously described15. Mice were fed with Lieber–DeCarli diet and the caloric intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in the early morning and killed 9 h later. Pair-fed control mice received a diet with an isocaloric substitution of dextrose.",8,ALD patent background + target paper.pdf,207,True
cb20161a2564d2d7216e477505fcbb8f,"Stool samples from patients with alcoholic hepatitis (Fig. 1) were used for faecal transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g stool dissolved in 30 ml Luria–Bertani (LB) medium containing 15% glycerol under anaerobic conditions), starting at an age of 5–6 weeks and repeated 2 weeks later. Two weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.",8,ALD patent background + target paper.pdf,208,True
8a6d17a0e3f64443f3390d86dca1c328,"In studies of the effects of cytolysin, 5 × 108 CFUs of a cytolytic E. fae- calis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2- 2(pAM771))5 (E. faecalis Δcytolysin) (kindly provided by M. S. Gilmore), or PBS (vehicle control) were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol feeding. Administration every third day was necessary, given that E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of phage",8,ALD patent background + target paper.pdf,209,True
f9d7bfe2eedac9500d5b3cdb1d356f97,"treat- ment, 1010 PFUs of E. faecalis phages (or C. crescentus phage phiCbK as control)35 were gavaged to the mice 1 day before the ethanol binge (at day 16). All animal studies were reviewed and approved by the Institu- tional Animal Care and Use Committee of UCSD.",8,ALD patent background + target paper.pdf,210,True
92ef1fa99dff370a9149c2961a1ed388,"The E. faecalis strain from Atp4aSl/Sl mice faeces has previously been isolated11 and was used to isolate phages Efmus1, Efmus2, Efmus3 and Efmus4 (phages specific to the E. faecalis strain isolated from mouse faeces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). E. faecalis strains from human stool samples were isolated using methods described below, and the cor- responding phages were named as Ef with patient number plus a digit (Ef for E.",8,ALD patent background + target paper.pdf,212,True
d3e8d3246d66c688354723e9dbcdf290,"E. faecalis phages were isolated from untreated raw sewage water obtained from North City Water Reclamation Plant in San Diego. Fifty millilitres of raw sewage water was centrifuged at 8,000g for 1 min at room temperature to pellet large particles. The supernatant was passed through a 0.45-μm and then a 0.2-μm syringe filter (Whatman, PES membrane). One hundred microlitres of the clarified sewage was mixed with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar)",8,ALD patent background + target paper.pdf,214,True
5a2ecb20b98679abe9ec4e7d4685525a,"and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, the resulting plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more times to ensure that the phages were clonal isolates.",8,ALD patent background + target paper.pdf,215,True
8aeb5a7c4f1f437cad055f2f2da16aae,"High-titre phage stocks were propagated by infecting 200 ml of expo- nentially growing E. faecalis at a multiplicity of infection of 0.1 in BHI broth containing 10 mM MgSO4. Lysis was allowed to proceed for up to six hours at 37 °C with shaking. The lysates were centrifuged at 10,000g for 20 min at room temperature to remove the remaining bacterial cells and debris. Supernatant was then vacuum-filtered through a 0.2-μm membrane filter and kept at 4 °C until use.",8,ALD patent background + target paper.pdf,216,True
b05d19fa5af188c7b8e5420e7cabc173,"Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF Concentrators with 100,000-molecular weight cutoff (MWCO) to a volume of approximately 1 ml. Following concen- tration, the culture medium was replaced with PBS via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml and adjusted to the required PFUs.",8,ALD patent background + target paper.pdf,217,True
a8bae4416c18abf2cac155e38c37d73a,"For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase and RNase at 37 °C for 1 h and phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4 °C overnight. Precipitated phages were then pel- leted by centrifugation at 10,000g for 10 min at 4 °C and resuspended in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA Clean-up kit (Promega). Phage genomes were",9,ALD patent background + target paper.pdf,219,True
59099ab5d3446bade1b274c1a33f5170,sequenced using a combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-based size selection before loading onto Illumina flow cells. Sequencing was performed with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) and loaded onto,9,ALD patent background + target paper.pdf,220,True
8bdbccea6236b8bbfd96fd480201388c,"MinION R9.4 flow cells. ONT reads were basecalled with Albacore v.2.3.4 (ONT). The sequence reads were demultiplexed and adapters trimmed from ONT reads using Porechop v.0.2.336. A hybrid Illumina-ONT de novo assembly was performed using the Unicycler v.0.4.7 pipeline37. Subsequently, Pilon v.1.2238 was used iteratively to polish the assemblies with Illumina reads until no addi- tional corrections could be made.",9,ALD patent background + target paper.pdf,221,True
ca35435b8ec55078f0a01c7a808831ea,"For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45-μm and 0.2-μm filters (VWR) and purified on a caesium chloride (CsCl) density gradient39. One millilitre of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qia- gen), amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a Bioruptor (Diagenode). Libraries were created using the Ion",9,ALD patent background + target paper.pdf,222,True
d2a1059394870487841ec6518e2f9ca7,"Plus fragment library kit and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 × coverage).",9,ALD patent background + target paper.pdf,223,True
1c53bab920a70926e09c18f7f7a39263,"Mapping of ONT reads to the hybrid assemblies was used to deter- mine the orientation and terminal ends of linear phage genomes, and reference genomes served as guides to orient circular phage genomes. Phage genome assemblies were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.",9,ALD patent background + target paper.pdf,224,True
91576a226a9cce9c84181d3e0cda5481,"Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3",9,ALD patent background + target paper.pdf,225,True
d23dd11e0d7d9d85c2aea1a91db70f28,"Genetic maps of phage genomes were generated by LinearDisplay. pl (https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://sourceforge.net/projects/mcj/) to render high- quality images. Preliminary annotation of genes was derived from the automated annotation and from Phage_Finder42, which uses curated hidden Markov models and databases of core phage gene to annotate core gene functions. Annotation was then manually reviewed to assign the final colours.",9,ALD patent background + target paper.pdf,227,True
a43d823c09b324b791bcb8beae797bac,"Phage phylogenetic tree

A phage whole-genome phylogeny tree was generated from a pairwise distance matrix calculated with the MASH program, which approxi- mates average nucleotide identity (ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated and sequenced in",9,ALD patent background + target paper.pdf,228,True
4e90311181576034039a159db8836df1,"this study plus 54 Enterococcus phage genomes obtained from Gen- Bank, with 5,000 12-mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial phage genome sequences to generate the ANI matrix using the mash distance command using default settings. The GGRaSP R package was used to calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI >99.985) were removed using the GGRaSP R package with a user",9,ALD patent background + target paper.pdf,229,True
006235dedb8b656ba8cae88658b1c5c8,"defined cutoff of 0.015 (ggrasp. cluster (threshold = 0.015)). The resulting dendrogram was translated into newick format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with taxonomic information and manually entered clade identification.",9,ALD patent background + target paper.pdf,230,True
26e716086b8135b36384ee83044eabb2,"DNA from human stool samples, mouse liver sections or bacterial cul- ture was extracted as previously described11, and DNA from mouse faeces was extracted using QIAamp Fast DNA Stool kit (Qiagen). 16S rRNA PCR was completed using Illumina adaptor and barcode-ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified using the Qiaquick PCR purification kit (Qiagen) using manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay",9,ALD patent background + target paper.pdf,233,True
702d4caabd5158cd933d728c9bc2cccf,"(Tecan), normalized and pooled in preparation for 16S rRNA sequencing. Pooled library was quantified and checked for qual- ity using Agilent 2100 Bioanalyzer (Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 cycles, 2 × 250-bp format using manufacturer’s specifications. 16S sequence reads were processed and operational taxonomic units were determined using our MOTHUR-based 16S rDNA analysis workflow as previously described11,49. Raw 16S",9,ALD patent background + target paper.pdf,234,True
ac97f219012f3111e9b6704302dea360,"Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and cylLL genes have previously been described50,51. All primers used in this study are listed in Supplementary Table 9. Mouse gene expression and amplification of bacterial genes were determined with Sybr Green",9,ALD patent background + target paper.pdf,237,True
bc267b0deb89a2c59e96f85c67de5eba,(Bio-Rad Laboratories) using ABI Ste- pOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 18S.,9,ALD patent background + target paper.pdf,238,True
a9f464facaa1cbf817a9c2422eaf8e4e,"To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial dilutions were made and 100 μl was placed on plates with selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the production of dark brown or black colour, generated by hydrolysis of esculin to esculetin (which reacts with ferric ammonium citrate). Each Enterococcus colony was then picked, and qPCR was performed to identify E.",9,ALD patent background + target paper.pdf,240,True
89cc95f4a0731b39a24a6b54c5a6ab46,"faecalis, using specific primers against the E. faecalis 16S rRNA gene50. For each subject, between 1 and 6 E. faecalis colonies were analysed and bacterial genomic DNA was then extracted as described in ‘Bacterial DNA extraction and 16S rRNA sequencing’.",9,ALD patent background + target paper.pdf,241,True
36cb8e6b2ee7ecc23a2b9f5175b6d079,DNA sequencing was performed on the Illumina HiSeq Ten X generat- ing paired-end reads (2 × 151 bp). Bacterial genomes were assembled,9,ALD patent background + target paper.pdf,242,True
099b7dfd205c297ccfd990d3aa6e41c5,"and annotated using the previously described pipeline52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes carried by E. faecalis isolates were identified by comparing individual genome assemblies against the CARD and VFDB databases, respectively, using abricate v0.8.10 (https://github.com/tseemann/abricate)53,54.",10,ALD patent background + target paper.pdf,244,True
4cd207c672357b22bc736d7265606756,"For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cutoff was used, and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this study have been deposited in the European",10,ALD patent background + target paper.pdf,245,True
160b9572e75fc7f21313c5b6fe72b406,"E. faecalis culture

All E. faecalis strains were grown statically in BHI broth or on BHI agar plate at 37 °C. Fifty micrograms per millilitre erythromycin was added when cytolytic and non-cytolytic E. faecalis strains were grown (Extended Data Fig. 2).",10,ALD patent background + target paper.pdf,247,True
0b3f87f0128253ff5d4a35973c23662d,"To determine levels of faecal enterococci in mice, 10–30 mg of mouse faeces was resuspended into 500 μl PBS and serial dilutions were made. Five microlitres of each dilution from each sample was spotted onto a plate with a selective medium, BBL enterococcosel broth (Becton Dickinson) and the plates were then incubated at 37 °C overnight. For Extended Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were identified by the production of a dark brown or black colour.",10,ALD patent background + target paper.pdf,249,True
6fbc1965b9031eac7d8fe0a1f15c0b0e,"To purify bioactive CylLL′′ and CylLS′′, an Escherichia coli heterologous expression system was used. In brief, either 6×His–CylLL or 6×His–CylLS were co-expressed with CylM (the enzyme that performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. The His tag and leader peptide were then removed using recombinant CylA (27–412), the soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive",10,ALD patent background + target paper.pdf,252,True
5aa1494873b653edbf3376e5eda334ee,CylLL′′ or CylLS′′. The resulting core peptides were further purified by reversed-phase high-performance liquid chromatography (HPLC).,10,ALD patent background + target paper.pdf,253,True
b31c744b5081aaac404dd88ef2fddd09,"The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 backbone vector that contained the cylM gene in MCSII6. The cylA (27–412) gene was previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star (DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, cylLS_cylM:pRSFDuet or cylA (27–412):pRSFDuet plasmids via KCM chemical transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 μg/ml) and",10,ALD patent background + target paper.pdf,254,True
409aae3f1eba8cc017c19167bc703e6f,grown at 37 °C overnight. One colony was picked to inoculate 15 ml of LB broth supplemented with kanamycin overnight at 37 °C. The culture was used to inoculate 1.5 l of terrific broth supple- mented with kanamycin. Cultures were grown with shaking at 37 °C to an optical density at 600 nm (OD600) of 0.8. The temperature of the incu- bator was lowered to 18 °C and expression was induced with the addi- tion of 0.3 mM final concentration of isopropyl β-d-thiogalactoside. The cultures were allowed,10,ALD patent background + target paper.pdf,255,True
8e5b87a0a6d982b36d840a001ad89e9e,"to incubate at 18 °C for 18 h. The cells were collected by centrifugation at 5,000g for 12 min. The cell paste was collected and frozen at -70 °C.",10,ALD patent background + target paper.pdf,256,True
95b7fab4c3c4954353259b85595a6288,"For the purification of the protease CylA (27–412), the cell paste was thawed and resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension was lysed by homogenization. The lysate was clarified by centrifugation at 13,000g for 45 min and filtered through a 0.45-μm centrifugal filter (Thermo Scientific). The clarified",10,ALD patent background + target paper.pdf,257,True
34a8543d6f0ed82dc1b09027480afb04,"lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a peristaltic pump. The loaded column was con- nected to an ÄKTA pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as determined by 4–20% SDS–PAGE, were combined, concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into",10,ALD patent background + target paper.pdf,258,True
caeefdcf1084e77ff5e6857cc445e3ff,"storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). Protein concentration was determined by absorbance at 280 nm.",10,ALD patent background + target paper.pdf,259,True
dca8b89b3f4eba96883fe6595de92729,"For the purification of CylLL′′ and CylLS′′ peptides, the cell paste was thawed and resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2-s pulse on, 5-s pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation at 13,000g for 45 min. The clarified cell lysate was filtered through a 0.45-μm centrifugal filter and applied via gravity flow to a pre-equili-",10,ALD patent background + target paper.pdf,260,True
c0fe84d533b3c2dc3baec429d45bd71d,"brated, 2 ml bed volume of His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The peptides were eluted with 10 ml of LanA elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final",10,ALD patent background + target paper.pdf,261,True
c5c35ee95bdcc35de798b9a11aa9ed68,concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.,10,ALD patent background + target paper.pdf,262,True
e23a4d1755011379bc6eca0c3bce3bfa,"The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. The solution was centrifuged at 4,500g for 10 min and filtered through a 0.45-μm syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse-phase HPLC using a Phenomenex Jupiter Proteo column (10 mm × 250 mm, 4 μm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were separated using a linear gradient of 3% (v/v) solvent B",10,ALD patent background + target paper.pdf,263,True
e7b6e4f32f22069121b573fc9ad95185,"(acetonitrile + 0.1% trifluoroacetic acid) in solvent A (water + 0.1% trif- luoroacetic acid). The fractions were spotted on a matrix-assisted laser desorption/ionization (MALDI) target plate by mixing 1 μl of sample with 1 μl of a 25 mg/ml solution of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were analysed by MALDI–time of flight (TOF) mass spectrometry on a Bruker UltrafleXtreme MALDI–TOF/ TOF operating in positive ionization, reflector mode.",10,ALD patent background + target paper.pdf,264,True
3a9f17d58ca5c1ed985aa20b6572a3e5,Hepatocytes were isolated from C57BL/6 female mice fed the chronic– binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced and filtered using a 70-μm nylon cell strainer. Hepatocytes were centrifuged at 50g for 1 min after 3 washes. Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher,10,ALD patent background + target paper.pdf,266,True
5507af1caa99c80bdb1e3ffd8d38a71b,"Scientific). Hepatocytes (1.5 × 105) were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin–transferrin–selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics. After 4 h, the culture was washed with DMEM-F12 medium and changed to the same complemented medium without FBS58. Then 16 h later, hepato- cytes were cultured with",10,ALD patent background + target paper.pdf,267,True
a7c38a89a8698c16dd863b474932e67e,Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride,10,ALD patent background + target paper.pdf,270,True
d49b5f36c647dff9812e57563fc16120,"Formalin-fixed tissue samples were embedded in paraffin and stained with H & E. To determine lipid accumulation, liver sections were embed- ded in OCT compound. Eight-micrometre frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). Representative images from each group of mice are shown in each figure. The terminal deoxynucleo- tide transferase-mediated dUTP nick-end labelling (TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly",11,ALD patent background + target paper.pdf,273,True
266821d571654b9cf819491e7ad4f506,"Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and multivariate Cox regression analysis was used to detect associations of cytolysin with overall mortality. The multivariate model was adjusted for geographical origin of the patients, antibiotic treat- ment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. Univariate logistic regression analysis of laboratory and clinical parameters associated with the detection of cytolysin and",11,ALD patent background + target paper.pdf,276,True
49a403ab85cf1287247d0dee3c6104d2,"E. faecalis was performed. Univariate linear regression analysis of labo- ratory and clinical parameters associated with the log-transformed total amount of faecal E. faecalis measured with qPCR was performed. To associate log-transformed total E. faecalis and E. faecalis positiv- ity with mortality, univariate Cox regression was used. P values from univariate and multivariate Cox regression, univariate logistic regres- sion and univariate linear regression were determined by Wald test.",11,ALD patent background + target paper.pdf,277,True
8d804e9fc95ed2db69557c927cb77778,"Multicollinearity was examined using the variance inflation factor. Kaplan–Meier curves were used to compare survival between cytolysin- positive and cytolysin-negative patients with alcoholic hepatitis. Faecal E. faecalis, bacterial diversity and richness from controls and patients were compared using Kruskal–Wallis test with Dunn’s post hoc test. Region- and/or centre-specific clinical characteristics of patients with alcoholic hepatitis were compared with Kruskal–Wallis test for continu- ous",11,ALD patent background + target paper.pdf,278,True
7b8dbc9af15bbcc3e361831b11ca9cb8,"and Fisher’s exact test for categorical variables. Faecal E. faecalis in patients with alcoholic hepatitis with or without cytolysin, and with or without cirrhosis, were compared with Mann–Whitney-Wilcoxon rank-sum test. Faecal E. faecalis in patients with alcoholic hepatitis from different region and/or centres were compared with the Kruskal– Wallis test. The percentage of subjects with faecal samples that were positive for E. faecalis and cytolysin was compared using Fisher’s exact test,",11,ALD patent background + target paper.pdf,279,True
f76e2fd0575907e2393cf2e9bac23226,"followed by FDR procedures for multiple group comparisons. Jaccard dissimilarity matrices were used for PCoA, and P values were determined by PERMANOVA followed by FDR procedures to correct for multiple comparisons.",11,ALD patent background + target paper.pdf,280,True
14e86a0ecd10b0bdc033d9707701e4ea,"For mouse and cell culture studies, the significance of multiple groups was evaluated using one-way or two-way ANOVA with Tukey’s post hoc test. Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for multiple comparisons. Kaplan–Meier curves were used to compare survival between experi- mental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed between experimental mouse groups and the P values were determined by PERMANOVA",11,ALD patent background + target paper.pdf,281,True
32c2ea73902ed3c942e714bd6eee2331,"Exact P values for all comparisons, together with group size for each group, were listed in Supplementary Table 10. Statistical analyses were performed using R statistical software, R v.3.5.1 (R Foundation for Sta- tistical Computing) and GraphPad Prism v.6.01. A value of P < 0.05 was considered to be statistically significant (adjusted for multiple comparisons when performing multiple tests).",11,ALD patent background + target paper.pdf,283,True
1bea2d99c1de3a43e7eef19cff96d941,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSa- mple identifiers (SAMN11089809–SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at the ENA under study PRJEB25007.,11,ALD patent background + target paper.pdf,287,True
5394a8c018c88ac0536804b7b2d6477f,"34. Krieg, L. et al. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood 118, 6418–6425 (2011).",11,ALD patent background + target paper.pdf,292,True
3f17dba3585624b45708b6cdb2c1a58d,"44. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

45. Letunic, I. & Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242–W245 (2016).",11,ALD patent background + target paper.pdf,298,True
f4bb22faef5daa08533bf8dfbc9d210b,"49. Chen, P. et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203–214.e16 (2015).",11,ALD patent background + target paper.pdf,301,True
f124b103101de64fc996b147c774e243,"57. Tang, W., Bobeica, S. C., Wang, L. & van der Donk, W. A. CylA is a sequence-specific protease involved in toxin biosynthesis. J. Ind. Microbiol. Biotechnol. 46, 537–549 (2019).",12,ALD patent background + target paper.pdf,308,True
185b9ea67d68e949dd1a9b4978ad85c7,"analysis and interpretation of data and key preliminary experiments; S. Lang, K.B., J.L. and X.M.T. provided assistance with statistical analysis; H.C., L.J., B.G., W.S., R.K., F.H. and S. Lee provided assistance with data acquisition; R.C.W., T.H.C., K.N., M.T. and D.E.F. were responsible for 16S rRNA sequencing, phage genome sequencing and data analysis; Y.S. and T.D.L. were responsible for bacterial genome sequencing and data analysis; A.H.-M., L.L. and R.Y. provided assistance with phage",12,ALD patent background + target paper.pdf,314,True
46c705e16cd763c9771436ac18f81264,[ - 00 Bacterial Genera Bacteroides Unclassified Lachnospiraceae Unclassified Ruminococcaceae 80 Veelllonella Akkermansia 70 Prevotella Blautia 60 Rosebuna Escherichia/Shigella Streptococcus 50 Unclassified Clostndiales 40 Dialister Faecalibacterium Clostndium_XiVa 30 Ruminococcus Enterococcus 20 Megasphaera Mogamonas Ruminococcus2 Relative sequence abundance (%) 10 Bifidobacterium | | = B Q=) = = - B: B ... [remaining 309 | Alcoholic Controls AUD hepatitis,13,ALD patent background + target paper.pdf,322,True
13c2eda700daeea7cfac4eeb693fd871,"75). c, E. faecalis in faecal samples from controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. d, Percentage of faecal samples positive for E. faecalis in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. E. faecalis was detected in faeces from 80% of patients with alcoholic hepatitis, versus 36% of controls (P < 0.001). There was also a significant difference between",14,ALD patent background + target paper.pdf,368,True
c6c794005ed2c243b6b65bc3dfd034cf,"or cytolysin-negative (n = 54), assessed by qPCR (P = 0.8174). g, 16S rRNA sequencing of faecal samples from patients with alcoholic hepatitis from different centres (France, n = 9; Mexico, n = 6; Spain, n = 5; UK, n = 11; USA (east), n = 16; USA (Midwest), n = 12; USA (west), n = 16 patients). We used PCoA based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between patients from different",14,ALD patent background + target paper.pdf,370,True
04f8e25335c7c097cf73a9f4a4bbef35,"regions (P < 0.01). h, Percentage of faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin- positive), in patients with alcoholic hepatitis from different centres (France,",14,ALD patent background + target paper.pdf,371,True
110198f4cecac26794a2b9b07553eeb2,"positive for E. faecalis in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.2878). Results are expressed as mean ± s.e.m. (c, f, i, l). For the box and whisker plots in b, the box extends from the 25th to 75th percentiles, and the centre line represents the median; for all three groups, the bottom whiskers show the minimum values; for the control group (black), the top whisker shows the maximum value; for the other two groups, the top",14,ALD patent background + target paper.pdf,374,True
fce98a9079b5963ef312b9f85de722b8,"whiskers represent the 75th percentile plus 1.5× the inter-quartile distance (the distance between the 25th and 75th percentiles); all values greater than this are plotted as individual dots. P values were determined by Kruskal– Wallis test (i) with Dunn’s post hoc test (b, c), two-sided Fisher’s exact test (h, j, k, m) followed by FDR procedures (d), two-sided Mann–Whitney Wilcoxon rank-sum test (f, l) or PERMANOVA (g). The exact group size (n) and P values for each comparison are listed in",14,ALD patent background + target paper.pdf,375,True
550684485674072abafcf4f167f8b82d,"lipopolysaccharide (LPS) by enzyme-linked immunosorbent assays. l, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices showed no significant differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following",16,ALD patent background + target paper.pdf,396,True
064f217c6f689fd99666e16faa4d30e3,"feeding with the control and ethanol diets. Compared to mice fed with a control diet, mice fed with an ethanol diet had significantly different faecal microbiomes after gavaging with E. faecalis (P < 0.05). m, n, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis after ethanol feeding. o, Mice were gavaged with cytolytic or non- cytolytic E. faecalis strains (carrying the",16,ALD patent background + target paper.pdf,397,True
f3de804e37dd92a77be6a081d904b203,"erythromycin resistance gene; 5 × 108 CFUs) at time 0, and faeces were collected 0, 8, 24, 48 and 72 h later. Faecal CFUs of Enterococcus were determined by culturing faecal samples on BBL enterococcosel broth agar plate with 50 μg ml-1 erythromycin. At time 0 and 72 h, five out of five and four out of five mice, respectively, had no detectable erythromycin-resistant Enterococcus in their faeces. These points are not shown on the graph, but have been included in the calculation of mean ± s.e.m.",16,ALD patent background + target paper.pdf,398,True
66a5c17e414f00a8c6cbd4f18aef4db9,"TUNEL AH cytolysin positive #1 r AH cytolysin positive #2 AH cytolysin negative #3 [N AH cytolysin negative #4 Percent positive (%) i il l 1l Control Ethanol

R Control . 3 /3% ¥ Ethanol F R o Ve, AH cytolysin AH cytolysin AH cytolysin AH cytolysin positive #1 positive #2 negative #3 negative #4

Cxcl2 Fold change - o oo 3 i Control Ethanol

Acta2 10 Fold change Control Ethanol",17,ALD patent background + target paper.pdf,401,True
ff9d64831d16a0ded96ff2e6dbab66ca,"colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, following the control diet. Mice transplanted with faeces from a cytolysin-positive patient with alcoholic hepatitis (patient",17,ALD patent background + target paper.pdf,408,True
8a092a9fc4f0f2e603dc4aec6e5ebda3,"no. 2) showed a microbiota that was significantly different to that of the other mouse groups following ethanol administration (P < 0.01). g, Percentage of cytolysin-positive E. faecalis in four patients with alcoholic hepatitis. Stool samples from the four patients were placed on plates with selective medium, and Enterococcus colonies were identified by the production of a dark brown or black colour. Enterococcus colonies were confirmed to be E. faecalis by qPCR. The cytolysin status of each E.",17,ALD patent background + target paper.pdf,410,True
4a5bb1e756991a1edd43066e311c2280,"results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001.",17,ALD patent background + target paper.pdf,412,True
7685edd1a6f2798486848d3a1a0c112f,"a Head s v % | . 2 | % o . Tail Siphophage Myophage Podophage (long, flexible, (contractile tail) (short, noncontractile tail) noncontractile tail) S5 or ¥ @ ¥ % Efmus1 Efmus2 Efmus3 Efm us4 Efmus1 (17,927 bp) y b Efmus2 (18,366 bp) Efmus3 (18,286 bp) T SN Efmus4 (18,186 bp) D ol | encapsidation/terminase [ tail fiber DNA polymerase | [l endolysin/lysin | I hypothetical protein - major capsid [ tail components [ DNA binding intron/intein [ holin Il ortal",18,ALD patent background + target paper.pdf,414,True
07050f0ff43493f216963888170f3067,"Serum ALT 500 — 400 ~300 200 - 100 ll WT II WT Atpas Control Ethanol

Hepatic triglycerides PBS C. crescentus phages 60 E. faecalis phages PBS C. crescentus phages EEEE E. faecalis phages '. i WT WT I/I Control Ethanol

S =y 5 Control "" | ey 3 - 3 Ethanol > R - 2 e PBS C. crescentus phages E. faecalis phages PBS C. crescentus phages E. faecalis phages WT Atp4ass

Cxcl1 15 es — e, 10 .- ""~ Fold change - o M | i WT WT /I Control Ethanol",19,ALD patent background + target paper.pdf,424,True
cfd6f71d41302ad17e0349d23f3478de,"Cxcl2 pes 3 — i - o - =3 Fold change ] . H - _ B L & WT I/ WT Control Ethanol

Liver cylLg 100 — s i 8 3 ] Percent mice (%) 8 2 nd o 3 /I WT / Control Ethanol

b S — e - o - o Fold change 5 SUs WT Atpda WT A Control Ethanol

Fecal Enterococcus 1010 10° 2108 108 10% il | 104 WT / WT / Control Ethanol

PBS a C. crescentus phages o8 E. faecalis phages o o & > Control PBS (10.08%) ] C. crescentus phages Atpdassi PC2 E. faecalis phages -1.0 4 17.1) 0",19,ALD patent background + target paper.pdf,425,True
97eea067db56287109cd9915c89a6f7c,"procedures (g) or PERMANOVA followed by FDR procedures (i). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",20,ALD patent background + target paper.pdf,447,True
d9d851e2342951de959914430e46830b,"Ef5.1 F)- ) ) o l ) ) o (41,141 bp) Ef5.2 (41,418 bp) ) b o s i D Ef5.3 F)- b ) o ol e ) ) (39,115 bp) Ef5.4 (41,141 bp) W) e om Ef2.1 (140,938 bp) PP o ) ) s o ) ) o D DO O OO 0 0 ¢ Ef2.2 ( W W (58,400 bp) L Ef2.3 i oo ) ) o (147,289 bp) ) ) m) m) o m m Capsid structural components Tail and baseplate and assembly assembly [ encapsidation/terminase [ tail fibers - DNA polymerase - endolysin/lysin - hypothetical protein (] major capsid - tail component [ DNA binding I holin intron/intein I rortal",21,ALD patent background + target paper.pdf,451,True
5e65bb528a0462abbeb41d6fda397cb8,"collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices shows no significant differences in the faecal microbiota of mice gavaged with control phage and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c–e, g, h). P values were determined by two-way",22,ALD patent background + target paper.pdf,463,True
3dcba7887dc4bafcba4fee83e5039e68,"ANOVA with Tukey’s post hoc test (a, c–e, g, h) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, ***P < 0.001.",22,ALD patent background + target paper.pdf,464,True
36746146626a68c1869d333cae1ffd69,"Ef6.1 ) b e o 4 (40,429 bp) Ef6.2 (17,966 bp) ) o Ef6.3 ) o (18,136 bp) Ef6.4 s ) o (41,133 bp) Ef7.1 D ) | (58,018 bp) - Ef7.2 1 ) o s (18,737 bp) Ef7.3 oo (18,818 bp) Ef7.4 (18,415 bp) C apsid structural components Other N and assembly || encapsidation/terminase [ tail fibers - DNA polymerase [ endolysin/ysin | [ hypothetical protein - tail component I intron/intein major capsid [ DNA binding [ holin I portal [ tail measure [ regulatory DNA recombination [l protease (scaffold protein) I",23,ALD patent background + target paper.pdf,466,True
045bb667bb02c256e39972e6453647d8,from GenBank (denoted by black letters) and 19 were from this study (4 phages against cytolysin-positive E. faecalis isolated from mice (shown in blue letters); 7 phages against cytolysin-positive E. faecalis isolated from patients with alcoholic hepatitis (shown in pink letters); and 8 phages against cytolysin- negative E. faecalis isolated from patients with alcoholic hepatitis (shown in green letters)) with Mash43 using a sketch size of s = 5000 and a k-mer size of k = 12 and GGRaSP59,24,ALD patent background + target paper.pdf,472,True
3339a5608a94dffc480710212d1278bb,"Control 1.0 C. crescentus phages g Cytolysin-positive E. faecalis phages | Patient #6 2 C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #7 g ] PC2 (19.54%) -0.5 -1.0 -1.0 1.0 PC1

Ethanol . - C. crescentus phages Cytolysin-positive E. faecalis phages Patient #6 0. C. crescentus phages u|| Cytolysin-positive E. faecalis phages Patient #7 0.0 PC2 (15.2%) -0.3 -0.2 0.2 0.50 (.)

Serum ethanol 1,000 800 (1] 600 I (mg/dl) 400 200 Patient Patient #6 #7 Ethanol",25,ALD patent background + target paper.pdf,479,True
e082f2210f85b74bb74f09ffc7ad7d30,"Extended Data Fig. 9 | Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages targeting non-cytolytic E. faecalis (1010 PFUs),",25,ALD patent background + target paper.pdf,481,True
1d7af732e5a50753c3d4a4b86ee5665e,"genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant difference in faecal microbiota among mice gavaged with control phages and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, g, h). P values were determined by two-way ANOVA with Tukey’s post",25,ALD patent background + target paper.pdf,484,True
a59fceee82250b70b476ce79598c3840,"For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described",26,ALD patent background + target paper.pdf,490,True
7283176899e9359a7761c62c0e8578cd,"solely by name; describe more complex techniques in the Methods section. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis",26,ALD patent background + target paper.pdf,491,True
744b1ea1b50d5157015a0ccb020f44ff,"testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated",26,ALD patent background + target paper.pdf,492,True
59cb227458d0170c095d9a964b471e9c,"Bacteriophage sequencing and phage tree: Albacore v2.3.4 (ONT), Porechop v0.2.3, Unicycler v0.4.7 pipeline, Pilon v1.22, CLC Genomics Workbench 4.9, NCBI Prokaryotic Genome Annotation Pipeline, in-house PERL script using Xfig, Phage_Finder, MASH program, GGRaSP and APE R-package, iTOL tree viewer 16S sequencing: MOTHUR-based 16S rDNA analysis workflow E. faecalis genome sequencing and tree: abricate v0.8.10 , Prokka, Roary, RAXML, iTOL Statistical analyses: R",26,ALD patent background + target paper.pdf,497,True
db919547ce2b2fb8114099bdb5949cb6,"For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",26,ALD patent background + target paper.pdf,499,True
02eed19603761eb3a5a1bfcd12f13125,"All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets",26,ALD patent background + target paper.pdf,501,True
a45bda3b81483a87565a5c5d14f72869,available at NCBI under the following consecutive BioSample IDs (SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at ENA under Study PRJEB25007.,27,ALD patent background + target paper.pdf,509,True
1782d002a5db530f4f0491d834b12409,"Sample size No power analyses or other calculations were used to predetermine sample sizes. Sample sizes were chosen based on prior literature using similar experimental paradigms (Nat Commun. 2017;8:2137; Gut. 2019;68:1504-1515) Data exclusions No data were excluded Replication In vivo experiments: more than two technical replicates (from different cohorts, on different dates), as well as biological replicates were performed to ensure data reproducibility; In vitro experiments: three",27,ALD patent background + target paper.pdf,514,True
31287eec58409495d16539420bfe7d0f,independent experiments and also replicates were performed on different dates to ensure data reproducibility. All replications were successful. Randomization Mice of similar age and weight were randomly assigned to experimental and control groups. Blinding The investigators were not blinded during cell and animal experiment assays.,27,ALD patent background + target paper.pdf,515,True
2a5b0b192987cbbcb213e79f0f5b91fc,"Ethics oversight All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.",27,ALD patent background + target paper.pdf,520,True
60bb3c1268359bab70329f41a916b08e,"Patients with alcohol use disorder fulfilling the DSM IV criteria (J Abnorm Psychol. 1997;106:545-553) were recruited from an alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a detoxification and rehabilitation program. Alcoholic hepatitis patients were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers in the USA, Mexico, United Kingdom, France and Spain. Detailed inclusion and",28,ALD patent background + target paper.pdf,527,True
9f978083d35ae2daa32d7ef55673dd5b,"The protocol was approved by the Ethics Committee of Hopital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San Diego",28,ALD patent background + target paper.pdf,530,True
3dff5bf0dd3d987610c819245891f764,"Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and",1,GvHD-paper.pdf,539,True
aaa0885b0f55e841fb07099e59cf25f8,"exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.",1,GvHD-paper.pdf,540,True
43c6d0fc9904d9d1a853af41520f416c,"are impor- tant causes of multidrug-resistant infections in patients (4). In single-center studies, E. faecium has been observed to dominate the fecal microbiota of immunocompromised patients after allogeneic hematopoietic cell transplantation (allo-HCT), a curative-intent therapy for hematological malignancies (5–7). Moreover, fecal domination with vancomycin- resistant enterococci increases the risk of",1,GvHD-paper.pdf,542,True
1b22244d9546e48c7c6e6d5783287762,"bloodstream infection in allo-HCT patients (5, 8). Patients with severe graft-versus-host disease (GVHD) after allo-HCT have poor outcomes with only ~30% long-term survival (9). Gut microbiota perturbations caused by broad-spectrum antibiotics and a reduction in microbial diversity are associated with in- creased transplant-related mortality and lethal GVHD in humans and mice (10–13). Besides causing infections, experimental studies in gno- tobiotic mice have revealed that enterococci play an",1,GvHD-paper.pdf,543,True
f61465198e6440e5f43238f30249cc80,"important role in colitis (14) by stimulat- ing antigen-presenting cells and CD4+RORg+ T cell infiltration, causing intestinal inflam- mation (15). In this study, we investigated the role of enterococci in the development of acute GVHD, both in allo-HCT patients and preclinical allo-HCT mouse models.",1,GvHD-paper.pdf,544,True
e4f3a612c5044eda5f3f1695a85bc930,We used 16S ribosomal RNA (rRNA) gene sequencing to study the fecal microbiota of 1325 adult allo-HCT recipients at four HCT centers: Memorial Sloan Kettering Cancer,1,GvHD-paper.pdf,545,True
b59c3859e6f00b6fade6679a559fc46d,"Center (MSKCC) (United States), Duke Uni- versity (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). Patient characteristics are shown in table S1. We observed high abundance of enterococci soon after transplantation in samples from all four transplant centers (Fig. 1B and fig. S1B). We defined Enterococcus domination as relative genus abundance ≥0.3 (≥30%) in any fecal sample, following a thresh- old we have used previously (5) (materials and methods and",1,GvHD-paper.pdf,546,True
ba5a7cd89a0dd0e1e025134ac812d2fa,"fig. S2C). The incidence of domination rose comparably across cen- ters, with up to 65% of patients exhibiting a domination event after allo-HCT (Fig. 1A). E. faecium was the dominant species in both the MSKCC and the multicenter-validation cohort (Duke, Hokkaido, and Regensburg) (Fig. 1B, fig. S1, and table S2), where 40.1% of MSKCC patients (441 of 1101 patients) and 46.0% of multicenter-validation patients (103 of 224 patients) met criteria for domination at any time point between day −20 and",1,GvHD-paper.pdf,547,True
07dfeaf72aaa01606b402fc242d17978,"early posttransplant period (day 0 to +21) was associated with significantly reduced overall survival and increased GVHD-related mortality in both the MSKCC and multicenter- validation cohort, as well as an increased risk of moderate-to-severe acute GVHD in the MSKCC cohort (Fig. 1, C and D, fig. S2, A and B, and table S3). The risk of relapse or disease progression was not associated with enterococcal domination in either cohort. The association of domination by genus Enterococcus with clinical",1,GvHD-paper.pdf,549,True
0b3f9ba03bbc4a8ad978c5a6129cefeb,"outcomes in the MSKCC cohort remained significant in a multivariate analysis adjusted for graft source, disease, conditioning intensity, gender, and age (table S4). In a subset of MSKCC patients, the vanA operon was found in 152 (37.4%) of 406 patients that had samples available for analysis, indicating the presence of vancomycin-resistant enterococci (VRE) (fig. S2E). Notably, expansions of several different taxa were detected in fecal samples in this study, but the Enterococcus genus was the",1,GvHD-paper.pdf,550,True
7167bbe87dc96d8199e21579ac3e08d9,"To further investigate these clinical obser- vations, we examined the fecal microbiota of mice early after transplantation using well- established mouse models of allo-HCT. In a major histocompatibility complex (MHC)– matched, minor-antigen-mismatched allo-HCT model [C57BL/6-to-129S1/Sv transplant (C57BL/ 6→129S1/Sv)], we performed 16S rRNA gene sequencing of fecal samples and found that E. faecalis dominated the fecal microbiota at posttransplant day +8 in mice who re- ceived T cell–replete",2,GvHD-paper.pdf,561,True
43839c87eb8aace015e7723f9fa7f14a,"grafts and developed lethal, acute GVHD (Fig. 2A and fig. S4A). In contrast to the patients who had pro- longed antibiotic exposures, this expansion of E. faecalis was independent of antibiotic administration and dependent upon GVHD, as it was not observed in control recipients of T cell–depleted allografts in which GVHD did",2,GvHD-paper.pdf,562,True
7684a55062ee8af4fdf8d0c77304a56f,"not develop. This posttransplant expansion of enterococci was consistently found in two additional lethal GVHD models: C57BL/6→ BALB/c mice (MHC-disparate model after ir- radiation conditioning) (Fig. 2B) and LP/ J→C57BL/6 mice [MHC-matched, minor- antigen–mismatched after busulfan and cyclophosphamide conditioning (16)] (Fig. 2C). The expansion of enterococci in murine allo- HCT recipients with GVHD was accompanied by an increase in Enterococcus colony–forming units recovered from mesenteric",2,GvHD-paper.pdf,563,True
aee0e1b81e7d3b79483c65310b022827,"Although we observed E. faecium domina- tion in patients and a transient expansion of E. faecalis in GVHD mice, we hypothesized that both members of this genus might be associated with GVHD. Of note, E. faecium",2,GvHD-paper.pdf,565,True
89027271151d4580fc1e3ab5a68f82c5,"only recently became recognized as a major human pathogen; before the 1990s it was E. faecalis that caused >90% of clinical in- fections (17). Because E. faecalis expands in mice with GVHD and is the major Enterococcus species in laboratory mice, we next investigated whether E. faecalis contributes to GVHD. We colonized germ-free C57BL/6 mice with a com- munity of six bacterial strains (Akkermansia muciniphila, Lactobacillus johnsonii, Blautia producta, Bacteroides sartorii, Clostridium bolteae,",2,GvHD-paper.pdf,566,True
0196242abc12beb7b4005908f58cc2d7,"and Parabacteroides diastonis; see materials and methods) (10, 18, 19) 21 days prior to allo-HCT (LP/J→gnotobiotic C57BL/6). One group of mice was cocolonized on day −21 with E. faecalis OG1RF, which remained detectable in mouse feces on days 0 and +7 (Fig. 2D, right panel, and fig. S4E). GVHD was exacerbated in E. faecalis–harboring mice",2,GvHD-paper.pdf,567,True
2e02651b2bf34489c2fbb4d5d62e9e86,E. faecium other E. spp. 1.00 E. faecium 0.60 E. cecorum M S E. durans 0.30 K C E. mundtii C 0.10 e c E. rivorum n a d E. moraviensis 0.01 n u E. gallinarum b a v 1.00 a E. lactis e l v i i d t E. malodoratus a a 0.60 l t e i r o E. ureasiticus n 0.30 c E. faecalis o h o 0.10 r t 0.01 20 60 80 −20 0 60 40 20 40 0 −20 80 day relative to HCT,2,GvHD-paper.pdf,573,True
d570fef3b0c8b7a841f6aa39ed31f5a9,Enterococcus domination of the gut microbiota [domination defined as a genus relative abundance of ≥0.3 (on a unitless scale from 0 to 1) over the course of allo-HCT (day −20 to +24 relative to HCT; using 7-day sliding windows) at different transplant centers]. (Right) Fraction of fecal specimens with enterococcal domination of the gut microbiota. (B) Relative abundance of different Enterococcus spp. in the microbiota of allo-HCT patients from the MSKCC and multicenter-validation cohort over the,2,GvHD-paper.pdf,577,True
9699d347d90b3ff6d6ed7bf145b4b245,"point represents a fecal sample, and color indicates the different Enterococcus spp.; the red dotted line indicates the threshold for domination set at a relative abundance ≥0.3. (C) Overall survival (left) and cumulative incidence of GVHD- related mortality (right) in the T cell replete graft recipients in the MSKCC patient cohort (see table S3), stratified into nondominated and Enterococcus- dominated groups (domination is defined as the relative genus abundance ≥0.3 in at least one sample",2,GvHD-paper.pdf,597,True
51c5aab43d05e63127bbe42b6cc4ad68,"BM+T 100 10"" ° 1 3x10* — BM (n=20) 102 107 2x10* — BM+T ® 50 102 10¢ g Enterococcus el.abundance 10+ A 19 o CFUs/g stool CFUs/mLN 1x10* 10° ° ) 10° o p<0.001 10 -1 4 7 10 10 7 10 0 5 10 15 20 days after HCT days after HCT days after HCT days after HCT c LP/J C57BL/6 16S rRNA feces Survival 14 days rel. to HCT o before bu/cy-cond 100 @ before HCT VVVYVYY v 1074 e BM ® BM+T — BM (n=9) AAA 1074 ¥ 50 g — BM+T (n=10) V busulfan g 'V cyclophosphamide Enterococcus rel. abundance 10° o 8 HCT p<0.01 10",3,GvHD-paper.pdf,607,True
6464d42cbded84d95353460653a01e18,"A allo HCTin AML patients == pre HCT/ non-dom. (i == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ Superpath. alanine biosyn. ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Calvin-Banson-Bassham cycld GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. Glycolysis IV P-diacylglycerol biosyn. | CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. N -2denosyl-L-methionine cycte | I",4,GvHD-paper.pdf,619,True
31cddea802aa517fb42fe13a7a3f3d9b,"A allo HCTin AML patients pre HCT (diverse) == pre HCT/ non-dom. (i M Enterococcus == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ B Akkermansia Superpath. alanine biosyn. W Blautia ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ W Clostridium Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Dorea Calvin-Banson-Bassham cycld Eubacterium GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. biosyn. ost HCT Glycolysis IV (E. F. domin.) I",4,GvHD-paper.pdf,621,True
851447f60b5755773ad526b4c7b664ba,F Clostridum vs. Enterococcus (genera) in allo-HCT patients Kendall tau =-0.21; p<0.001 1 3 o = 3 2 B o Clostridium 3 2 rel. abundance - 0 107 107 1 Enterococcus rel. abundance,4,GvHD-paper.pdf,637,True
2498ac75135d91cdb2352300d0b9073f,Kendall tau =-0.15; p = 0.008 20 0o butyrate mM oo 3 - orts o 0 107 10 _I- Enterococcus rel. abundance,4,GvHD-paper.pdf,651,True
cffa761b3293f1bad8dc1fd8805a8bb6,"vated and proliferating CD4+ T cells (fig. S4D; CD4+CD25+; CD4+Ki67+), and an increased number and percentage of CD4+RORg+ T helper 17 (TH17) cells in colon lamina propria (fig. S4D). Posttransplant administration of E. faecalis",5,GvHD-paper.pdf,658,True
dcee265dde1662d9b5135c2a51aa3aa4,"OG1RF to conventionally housed, T cell–replete bone marrow (BM+T)–transplanted BALB/c mice also aggravated GVHD (fig. S5A). These findings indicate that E. faecalis can aggravate GVHD severity.",5,GvHD-paper.pdf,664,True
0e59ef689baac0d6e83daed3d3dc10b2,"Statistical analysis of box plot data: *P < 0.05 (Wilcoxon rank test). (D) Cumulative incidence of acute GVHD grade 2 to 4 in rs4988235 SNP-genotyped MSKCC patients (T cell–depleted grafts excluded; graft source: BM/PBSC unmodified = 213 patients; cord blood = 102 patients; C/C = 175, T/C+T/T = 140). The cumulative incidence of grade 2 to 4 acute GVHD was compared between genotype groups using the R package cmprsk.",5,GvHD-paper.pdf,673,True
5a6c1e16a3e36906a3e2d3a8a327fc54,"We next considered whether posttransplant defects of mucosal defense mechanisms facil- itate enterococcal expansion. Immunoglobulin A (IgA) coating of intestinal bacteria can be protective in colitis and is important for maintaining mucosal integrity (20). How- ever, we did not observe members of the genus Enterococcus to be enriched in either IgA- negative or IgA-positive fecal fractions, even though total fecal IgA was significantly re- duced in allo-HCT recipients with GVHD (fig. S5, B to D).",6,GvHD-paper.pdf,689,True
d2fd496bdfe0b7e7b6ce33f463067ead,"Reduction of IgA by transplant- ing IgA-deficient bone marrow (BM) from activation-induced cytidine deaminase knock- out mice did not further increase enterococcal expansion (fig. S5E). Intestinal antimicrobial peptides of the Reg3 family can suppress the growth of VRE (21) and are reported to play a major role in GVHD (22). Accordingly, we found that both Reg3B/G transcripts and interleukin-22 protein, which regulates Reg3 expression (23), were reduced in the ileum of GVHD mice (fig. S5F).",6,GvHD-paper.pdf,690,True
f437430e0d1cd83772d368fde5605c8c,"Next, we analyzed microbiota-intrinsic fac- tors and used shotgun metagenomic sequenc- ing to characterize the metabolic potential of the Enterococcus-dominated fecal microbiota. Pre- and posttransplant fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia were selected for sequencing on the basis of having a highly diverse pre-HCT microbiota and posttrans- plant E. faecium domination (by 16S rRNA gene sequencing). We focused on microbial metabolic pathways that",6,GvHD-paper.pdf,691,True
954c9a9e57f11308dd3b33e7774937ff,"specifically charac- terize domination by comparing them with the highly diverse pretransplant microbiota from the same patients. Pathways involved in DNA synthesis and, notably, in lactose and galactose degradation were enriched in the E. faecium–dominated, posttransplant micro- biota. In contrast, amino acid synthesis and starch-degradation pathways were more prev- alent in pretransplant specimens (Fig. 3A). The lactose-and-galactose degradation path- way was also significantly enriched in the",6,GvHD-paper.pdf,692,True
1763b36f0e868d4f3f751a78c1fadc47,posttransplant E. faecalis–dominated samples of mice with GVHD (Fig. 3B). Comparison of whole-genome sequencing from isolates of E. faecium (from a human allo-HCT patient) and of E. faecalis (from a mouse with GVHD) revealed that genes encoding lactose and galactose metabolism accounted for ~3% of their genomes (Fig. 3C). In silico analysis of these Enterococcus genomes and publicly available genomes of other members of the gnotobiotic six-strain consortium revealed that enterococci are,6,GvHD-paper.pdf,693,True
5fb0585b5d598332dbfa0df06c2d09af,"specifically enriched in enzymes of the tagatose-type galactose path- way for galactose-to-glucose degradation (24) (materials and methods and fig. S6, A and B). Enterococcal growth depends on lactose in vitro, as both E. faecalis and E. faecium strains cultured in brain-heart",6,GvHD-paper.pdf,694,True
f40eea9163a0eafca1c765d2532619da,"infusion (BHI) broth depleted of lactose (by lactase; fig. S7A) did not grow (Fig. 3D). Growth was reinstated upon transfer to re- gular BHI, excluding antibacterial effects of lactase treatment (Fig. 3D). Enterococcal expansion after allo-HCT was accompanied by a loss of Clostridium spp. in the microbiota of allo-HCT patients (Fig. 3, A and F) and of mice with GVHD (fig. S8, A to C, and table S7). This may be important for allo-HCT patients, as high abundances of clostridia are associated with",6,GvHD-paper.pdf,696,True
83a84cf1c218335bbe5608707fd742dd,"better survival and low- er incidence of GVHD (12, 25). Commen- sal clostridia are known to produce large amounts of butyrate (26), which mitigates lethal GVHD in mice through protecting energy homeostasis of enterocytes (27). We observed that posttransplant enterococcal domination and a loss of clostridia were accompanied by a significant reduction in fecal butyrate in both allo-HCT patients and mice with GVHD (Fig. 3, E and G) (28). A loss of this key metabolite may contribute to the poor",6,GvHD-paper.pdf,697,True
b588c6e7e34cada90b753ddcecf6c937,"Given that the optimal growth of enterococci depends on lactose availability in vitro, we investigated whether enterococcal expansion can be mitigated by feeding mice lactose-free chow (fig. S7B and table S8). In the C57BL/ 6→BALB/c model, the absence of dietary lactose significantly reduced posttransplant Enterococcus bloom and mitigated GVHD (Fig. 4A and fig. S9B). Flow cytometric anal- ysis of donor T cells on day +14 revealed a reduction in the percentage of activated and proliferating CD4+",6,GvHD-paper.pdf,699,True
bbddbe11309e15be8746bc6e6d43c2f6,"T cells (CD4+CD69+; CD4+ Ki67+) as well as a reduction in the percent- age of CD4+Tbet+ (TH1) T cells (fig. S9). The effect of a lactose-free diet on enterococcal outgrowth and GVHD was replicated in the LP/J→C57BL/6 mouse model (Fig. 4B and table S9 for changes in non-enterococcal taxa). Intestinal mucosal damage by irradiation or allo-reactive T cells may affect the expres- sion of lactase, the enzyme found on small- intestine enterocytes that facilitates lactose absorption through",6,GvHD-paper.pdf,700,True
9580a38a6bd2010ce8455948bca92bea,"Next, we explored whether enterococci ex- pansion is associated with lactose tolerance in human allo-HCT patients by genotyping 602 patients from the MSKCC cohort with available pretransplant germline DNA sam- ples for the gene polymorphism rs4988235 (-13910*T). This single-nucleotide polymorphism (SNP) regulates lactase expression and pre- dicts lactose absorption and/or tolerance (C/T",6,GvHD-paper.pdf,702,True
e5a71d616a1f5fa0cabb719adc207bb7,"or T/T alleles) and malabsorption (C/C alleles) in the upper gut (29). Although abundance of the genus Enterococcus increased comparably during exposure to broad-spectrum antibiotics in both lactose absorbers and malabsorbers, enterococcal domination was significantly prolonged in malabsorbers after cessation of antibiotics (Fig. 4D and fig. S10). This finding suggests that the maintenance of enterococ- cal domination and microbiota recovery after broad-spectrum antibiotic exposure is signif-",6,GvHD-paper.pdf,704,True
b6a05d64d49450dd0c8ef03617fcb46d,"significant risk factor for the development of acute GVHD and for increased overall and GVHD-related mortality after allo-HCT. Our findings extend previous reports from smaller single-center analyses that posttransplant VRE bacteremia and fecal domination are associated with worse outcomes after allo-HCT (7, 8, 30). In gnotobiotic mouse models, enterococci exacerbate GVHD, consistent with previous reports of aggravated colitis in models of in- flammatory bowel disease (14) or systemic autoimmune",6,GvHD-paper.pdf,706,True
1c6bb1dfa8db30e79c638bec74376d1f,"responses (31). We previously identified Blautia abundance (a genus within class Clostridia) as a predictor of protection from lethal GVHD (12), whereas here we describe Enterococcus domination as a risk factor for GVHD. These two findings are noteworthy in light of our recent observa- tion that a B. producta strain can inhibit VRE growth via the production of a lantibiotic pro- tein (32). We identified a microbiota-intrinsic mechanism that is dependent on lactose uti- lization and favors the",6,GvHD-paper.pdf,707,True
cc33c91f1130a936ee46c6ae310e78a0,"expansion of enterococci. This process may be triggered through a loss of lactase produced by enterocytes damaged by conditioning or allo-reactive T cells. We validated this concept experimentally, by showing that depletion of lactose in vitro and in vivo inhibited enterococcal expan- sion and mitigated GVHD, and clinically, by showing that patients harboring a lactose- malabsorption allele experienced prolonged Enterococcus domination after antibiotic ex- posure. These observations in mice and",6,GvHD-paper.pdf,708,True
1871f55a7f0f2c529f132e462c348f1a,"Investigator Award/Gilead Sciences (N.K.); NIH KL2 TR001115-03 (NCATS CTSA to A.D.S.); NIA 2P30AG028716-11 (Claude D. Pepper Older Americans Independence Center to A.D.S.); NCI R01CA203950-01 (to N.J.C., A.D.S., L.B., M.L, and A.B.); NIH 1R01HL124112-01A (A.D.S. and R.R.J.); and NIA R21AG066388- 01 (A.D.S. and N.J.C.). Author contributions: C.K.S.-T., E.G.P., J.U.P, and M.R.M.v.d.B. conceptualized the project; C.K.S.-T., A.L.C.G., A.S., S.D., A.P., J.R.C., Y.T., R.R.J., J.B.X., E.R.L., and",7,GvHD-paper.pdf,725,True
098e8540f566a36f09c7ff336ae43224,"project and provided validation; and C.K.S.-T., J.U.P., A.L.C.G., and M.R.M.v.d.B. prepared data presentation and wrote the manuscript with contributions from all other authors. Competing interests: M.R.M.v.d.B has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia",7,GvHD-paper.pdf,728,True
3ce3922fd862b683589b6308cb40b131,"Ferring Pharmaceuticals; is an inventor on patent application number WPO2015179437A1, entitled “Methods and compositions for reducing Clostridium difficile infection,” and patent number WPO2017091753A1, entitled “Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization”; and holds patents that receive royalties from Seres Therapeutics Inc. Other authors have no competing interests. Data and materials availability: All data are available in the manuscript",7,GvHD-paper.pdf,730,True
95242abae2592d3655f378dd677c95b1,Lactose drives Enterococcus expansion to promote graft-versus-host disease,8,GvHD-paper.pdf,740,True
3a2aa0457adcaff586239378cb1d9d6e,"Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to",8,GvHD-paper.pdf,745,True
4b00abb7d1147c6075f334a2fe5f2f66,"provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models.",8,GvHD-paper.pdf,746,True
=======
element_id,text,page_number,filename,chunk_id,relevant
26e2ffa12765874ed647b25892f5742c,Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease,1,ALD patent background + target paper.pdf,2,True
a97990c757688b2ad9f9547223e628af,"Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol- induced liver disease in mice4, but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin—a two-subunit exotoxin that is secreted by Enterococcus faecalis5,6—as a cause of hepatocyte death",1,ALD patent background + target paper.pdf,7,True
7700e213119d995bb900c028b2058ba8,"and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of",1,ALD patent background + target paper.pdf,8,True
55628f8d8fcd11065a2f49008a2a0a12,"bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort",1,ALD patent background + target paper.pdf,9,True
4d0808dcc0de15622ab920197f3e824e,"The most severe form of alcohol-related liver disease is alcoholic hepa- titis; mortality ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a diagnosis of severe alcoholic hepatitis7–9. Therapy with corticosteroids is only marginally effective9. Early liver transplantation is the only curative therapy, but is offered only at select centres and to a limited group of patients10.",1,ALD patent background + target paper.pdf,11,True
06eaaa92b96ca86c0147a2adb438eadb,Alcohol-related liver disease can be transmitted via faecal micro- biota4. We investigated the microorganisms and microbial factors that are responsible for this transmissible phenotype and for progression of alcohol-related liver disease.,1,ALD patent background + target paper.pdf,12,True
7d4f7d11058fefb73c25d74168a266b2,"with an altered composition of the faecal microbiota. Differences in faecal microbiota composition were noted in patients with alcohol-use disorder and alcoholic hepatitis, compared to subjects without alcohol- use disorder (controls) (Fig. 1a, Extended Data Fig. 1a, b, Supplementary Tables 1, 2). One substantial difference that we observed was an increase in the proportion of Enterococcus spp. in patients with alcoholic hepa- titis: in these patients, 5.59% of faecal bacteria were Enterococcus",1,ALD patent background + target paper.pdf,16,True
5d8c1ebe16d59c1d317dffc791695a29,"spp. compared with almost none in controls (0.023%; for comparison, 0.004% of all reads were Enterococcus spp. in the Human Microbiome Project) or patients with alcohol-use disorder (0.024%). Faecal sam- ples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls, as measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), which is consistent with the 16S rRNA sequencing results. About 80% of patients with alcoholic hepatitis are positive for",1,ALD patent background + target paper.pdf,17,True
2a0fa3f8a748f185786faa503f15c12e,"with faecal samples that were positive for both cylLL and cylLS DNA sequences (cytolysin-positive), in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. Statistically significant differences were detected between controls and patients with alcoholic hepatitis (P < 0.01), and between patients with alcohol- use disorder and patients with alcoholic hepatitis (P < 0.001). c, Kaplan–Meier curve of survival of patients with alcoholic",2,ALD patent background + target paper.pdf,30,True
c0cb33fc914a181a931f63d3f064994f,"hepatitis whose faecal samples were cytolysin-positive (n = 25) or cytolysin-negative (n = 54) (P < 0.0001). d, Core genome single-nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis (n = 93 strains, from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. faecalis. Genomically identical isolates from the same patient were combined, and are shown as a single dot. Scale bar represents the nucleotide substitutions per",2,ALD patent background + target paper.pdf,31,True
5f83e60c4dddb2f0280d1a7e278bce89,"SNP site. P values are determined by permutational multivariate analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR procedures (b) or two-sided log- rank (Mantel–Cox) test (c). The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",2,ALD patent background + target paper.pdf,32,True
561904fc909fe66441a85e2fd6b522a7,"The colonization of mice with E. faecalis induces mild hepatic stea- tosis and exacerbates ethanol-induced liver disease11, by mechanisms that are unclear. Cytolysin is a bacterial exotoxin (or bacteriocin) that is produced by E. faecalis12, and which contains two post-translationally modified peptides (CylLL′′ and CylLS′′) in its bioactive form6. The two peptides are encoded by two separate genes: cylLL and cylLS, respec- tively12. Cytolysin has lytic activity against not only Gram-positive",2,ALD patent background + target paper.pdf,33,True
611eb13b2d6e50c5fddc28b53f5e5681,"bacte- ria, but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA (cytolysin-positive) in faecal samples from 30% of patients with alco- holic hepatitis; none of the faecal samples from controls and only one sample from a patient with alcohol-use disorder was cytolysin-positive, as detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-positive patients with alcoholic hepatitis died within 180 days of admission, compared to only 3.8% of cytolysin-negative patients (P < 0.0001)",2,ALD patent background + target paper.pdf,34,True
143566463ffffbf593619724e143bd32,"(Fig. 1c). Among the cytolysin-positive patients, 72.2% (13 out of 18) died owing to liver failure (including complications related to liver",2,ALD patent background + target paper.pdf,35,True
caa8512566105619e699d5975503c375,"failure, such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not associated with 30-day, 90-day or 180-day mortality (P = 0.403, 0.234 or 0.098) in patients with alcoholic hepatitis.",2,ALD patent background + target paper.pdf,37,True
79535293be1afc815d786a3f02a7f4b1,"Our univariate logistic and Cox regression of laboratory and clinical parameters found an association between the detection of cytolysin- encoding genes in faeces and the international normalized ratio (INR), platelet count, the model for end-stage liver disease (MELD) score, the sodium MELD score, the age, serum bilirubin, INR and serum creatinine (ABIC) score and death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding genes in faeces was associated with",2,ALD patent background + target paper.pdf,38,True
e6d629f4b1c9cb4dc395249f617132df,"90-day (P = 0.004) and with 180-day mortality (P = 0.001) (Supple- mentary Table 3), even after we adjusted for the geographical origin of the patient, antibiotic treatment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. We found no multicollinear- ity between the detection of faecal cytolysin-encoding genes and these cofactors (variance inflation factor < 1.6), which indicates that cytolysin is an independent predictor of mortality in patients with alcoholic",2,ALD patent background + target paper.pdf,39,True
94cde9ce9ef95ccd106fb02ae05cfb3e,"hepatitis. When we performed receiver-operating-characteristic curve analysis for 90-day mortality, cytolysin had an area under the curve of 0.81, which was superior to other widely used predictors for mortality in clinical practice (Extended Data Fig. 1e). On the basis of our findings, we propose that the detection of cytolysin may be a prognostic factor for more severe liver- related outcomes and increased risk of death, and a stronger predictor of mortality than MELD, ABIC and the",2,ALD patent background + target paper.pdf,40,True
902cf4996a4515d0de2f125dc02eddb3,"To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed targeted culturing from stool samples. Whole- genome sequencing of 93 E. faecalis isolates revealed a broad phylo- genetic diversity of cytolysin-positive E. faecalis from patients with alcoholic hepatitis (Fig. 1d), which indicates that cytolysin production is a variable trait among E. faecalis isolates and that cytolysin is car- ried in mobile genetic elements, which include both chromosomally encoded",2,ALD patent background + target paper.pdf,42,True
ebbb35022ddcef9c9c90ac7e6187c74d,pathogenicity islands and plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Table 4).,2,ALD patent background + target paper.pdf,43,True
4715251334e04eee26610aa45866c63d,"The total amount of faecal E. faecalis, or faecal E. faecalis positivity, did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5, 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar amounts of faecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the composition of the gut microbiota in patients with alcoholic hepatitis from different geographical regions (Extended Data",2,ALD patent background + target paper.pdf,44,True
f6ecdb28a54e5d4d94f4a14a103736db,"Fig. 1g), the proportion of cytolysin-positive patients, total amount of faecal E. faecalis, faecal E. faecalis positivity (Extended Data Fig. 1h–j), treatment and clinical outcomes (30-day and 90-day mortality) did not differ significantly among the regions or centres (Supplemen- tary Table 7). In addition, cirrhosis was not associated with cytolysin positivity, the total amount of faecal E. faecalis or faecal E. faecalis positivity in patients with alcoholic hepatitis (Extended Data Fig. 1k–m,",2,ALD patent background + target paper.pdf,45,True
e6db8bdc4405a6e2124134e9bb1b881b,Supplementary Tables 4–6). These results confirm our findings that the presence of cytolysin-producing E. faecalis rather than the total amount or presence of E. faecalis per se determines the severity of alcoholic hepatitis and mortality.,2,ALD patent background + target paper.pdf,46,True
4394ea43077688af40457154fcf3fe86,"To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we gavaged mice with a cytolytic E. faecalis strain (FA2- 2(pAM714)) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol diet15. Compared to mice gavaged with phosphate-buffered saline (PBS), mice fed with ethanol after they were gavaged with cytolytic E. faecalis developed more severe liver injury as indicated by a higher level of alanine amino-",2,ALD patent background + target paper.pdf,48,True
803be30d6b7b9beb9e0d255c9c9300e4,"groups, right), and incubated with vehicle, CylLS′′, CylLL′′ or both of the cytolysin subunits at the indicated concentrations without (–) or with (+) ethanol (25 mM) for 3 h. The survival of hepatocytes was determined in three independent experiments. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h). P values are determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures (g) or",3,ALD patent background + target paper.pdf,71,True
fd3e1df3ce5c323b45e75f5eaef59c84,"two-way ANOVA with Tukey’s post hoc test (h). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",3,ALD patent background + target paper.pdf,72,True
c721bc91a482f5706172d5baa91a3482,"were gavaged with cytolytic E. faecalis also had more liver inflamma- tion with higher expression levels of mRNAs that encode inflamma- tory cytokines and chemokines (Il1b, Cxcl1 and Cxcl2) (Extended Data Fig. 2d–f), compared with mice given PBS. Mice that were fed ethanol after they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver injury, steatosis and inflammation (Extended Data Fig. 2a–f) and longer survival times (Extended Data Fig. 2g), as compared",3,ALD patent background + target paper.pdf,73,True
549e1cb07f3051eab773a26b636ae6b4,"To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in the liver. CylLS was significantly increased in the liver of mice given cytolytic E. faecalis but not in the liver of mice that were not given E. faecalis or of mice gavaged with non-cyto- lytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable in the liver of mice given cytolytic and",3,ALD patent background + target paper.pdf,75,True
b475e1e40238cbba321930bb216f97e5,"non-cytolytic E. faecalis and fed an ethanol diet, but not when mice were fed an isocaloric (control) diet (Extended Data Fig. 2i); this indicates that ethanol-induced changes in the gut barrier are necessary for the translocation of cytolytic E. faecalis from the intestine to the liver. The livers of ethanol-fed mice that were given cytolytic or non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed an increased intestinal permeability in ethanol-fed",3,ALD patent background + target paper.pdf,76,True
c1a4bb6c553d4c3522586bf5dca2d7c3,"Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change the composition of the intestinal microbiota, as shown by 16S rRNA gene sequencing (Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic metabolism",3,ALD patent background + target paper.pdf,78,True
087245f4a6bfbf0ce492cdb0a56d81d7,"chronic–binge feeding model, gavaged with control phages against C. crescentus (1010 plaque-forming units (PFUs)) or a cocktail of three or four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT.",4,ALD patent background + target paper.pdf,102,True
d253e3a43ab52f08a6245d521ebcb8d0,"of ethanol, as indicated by serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs (which encode the two primary enzymes that metabolize ethanol in the liver) (Extended Data Fig. 2m, n). These results indicate that E. faecalis that produce cytolysin promote ethanol- induced liver disease in mice.",4,ALD patent background + target paper.pdf,105,True
ffdc6a9c01768b9a6dedf3176294f83d,"To extend our findings to humans, we colonized germ-free mice with faeces from cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobi- otic C57BL/6 mice colonized with faeces from two cytolysin-positive patients developed more severe ethanol-induced liver injury, steatosis, inflammation and fibrosis than mice given faeces from two cytolysin- negative patients (Fig.",4,ALD patent background + target paper.pdf,106,True
3575029f1aaf0a5f7162ca210a4d3957,"cytolytic E. faecalis to the liver after ethanol administration (Fig. 2g). The overall composition of the intestinal microbiota was not differ- ent between mice fed the control diet and colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, as shown by 16S rRNA gene sequencing. Mice transplanted with faeces from one of the cytolysin-positive patients with alcoholic hepatitis (patient no. 2) showed a microbiota that was significantly different from",4,ALD patent background + target paper.pdf,109,True
6e607ff4fcf96493e90864e165d30e92,"that of the other mouse groups after ethanol administration (Extended Data Fig. 3f). Non-cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorp- tion or hepatic metabolism of ethanol between mice colonized with faeces from cytolysin-positive versus cytolysin-negative patients (Extended Data Fig. 3h, i). Together, these results provide further evi- dence that cytolysin promotes",4,ALD patent background + target paper.pdf,110,True
f4e427a72049170a6628d99269b98ce6,"To determine the mechanism by which cytolysin increases liver dis- ease, we isolated hepatocytes from mice fed ethanol or control diets, and stimulated them with pure bioactive cytolysin peptides (CylLL′′ and CylLS′′)6. Incubation of the primary mouse hepatocytes with the two cytolysin subunits caused a dose-dependent increase in cell death compared to hepatocytes that were incubated with vehicle or with one subunit only (Fig. 2h). When we isolated hepatocytes from ethanol-fed mice and then",5,ALD patent background + target paper.pdf,140,True
214ae1e568b34b33b939e97c1f233f1c,"incubated these hepatocytes with ethanol, we did not observe increased levels of cytolysin-induced cell death compared to hepatocytes isolated from mice on the control diet, which indicates that cytolysin-induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are possibly mediated by pore forma- tion, resulting in cell lysis14.",5,ALD patent background + target paper.pdf,141,True
20fc8211be2207f7ebbc1f9da4b90d6b,"we investigated the effects of treatment with bacteriophages (here- after, phages). Phages are ubiquitous in bacteria-rich environments, including the gut16. E. faecalis phages that are highly strain-specific can be isolated17, which potentially makes the direct editing of gut microbiota feasible. It has previously been shown that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, which is associated with increased susceptibility to alcohol-induced",5,ALD patent background + target paper.pdf,146,True
f783833317fcda1d67fae16824103ca1,steatohepatitis11. The gavaging of wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice led to increased ethanol-induced steatohepatitis11. We found that this same E. faecalis strain expressed cytolysin. We then isolated four distinct phages from sewage water. These phages lyse the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type littermates,5,ALD patent background + target paper.pdf,147,True
d9ac1b615fdd2bf5e600d7df13fec8de,"Compared to Atp4aSl/Sl mice gavaged with control phages or vehicle, Atp4aSl/Sl mice gavaged with phages that target cytolytic E. faecalis had less severe liver injury, steatosis and inflammation after chronic ethanol feeding (Extended Data Fig. 5a–f). Administration of E. faecalis phages significantly reduced levels of cytolysin in the liver (Extended Data Fig. 5g) as well as faecal amounts of Enterococcus (Extended Data Fig. 5h). Phage administration did not affect the overall composition of",6,ALD patent background + target paper.pdf,151,True
fcaf8ee93aa30caad09e40b224cb1dc1,"To develop a therapeutic approach to precisely edit the intestinal microbiota, we cultured cytolytic E. faecalis strains from the faecal samples of patients with alcoholic hepatitis. We then isolated lytic phages from sewage water against these cytolytic E. faecalis strains; these phages had siphophage or myophage morphology (Fig. 3a, Extended Data Fig. 6). Gnotobiotic mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (Sup- plementary Table 8) and",6,ALD patent background + target paper.pdf,153,True
baf51e181775b4dcfa74544228c84273,"given three or four different—but patient- specific—lytic phages against cytolytic E. faecalis. The phages against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, as shown by lower levels of ALT, lower percentages of hepatic cells positive for terminal deoxynucleotide transferase-mediated dUTP nick-end labelling, and lower levels of hepatic triglycerides and oil red O-staining (Fig. 3b–d, Extended Data Fig. 7a, b), as well as by decreased hepatic levels of Il1b,",6,ALD patent background + target paper.pdf,154,True
10f2c121251e7865f10e7f5043ac0bc3,"Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLS, as compared with mice given control phages (against C. crescentus) (Fig. 3e–h, Extended Data Fig. 7c, d). Treatment with phages against cytolytic E. faecalis also reduced faecal amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were similar in all groups (Extended Data Fig. 7g, h).",6,ALD patent background + target paper.pdf,155,True
da9fd7f19241044c965123053eb42f33,"To demonstrate that the effect of phage treatment occurs via the targeting of cytolysin-positive E. faecalis, rather than a reduction in cytolysin-negative E. faecalis, we colonized gnotobiotic mice with faeces from cytolysin-negative patients with alcoholic hepatitis (Sup- plementary Table 8). Phages against non-cytolytic E. faecalis from patients were isolated from sewage water; they had siphophage or podophage morphology (Fig. 4a, Extended Data Fig. 8). These phages did not reduce features of",6,ALD patent background + target paper.pdf,156,True
60dd9e4ba9b6783c14557df1602b62e3,"ethanol-induced liver disease compared with control phages (Fig. 4b–g, Extended Data Fig. 9a–h), despite the reduc- tion of faecal Enterococcus (Fig. 4h). Our findings indicate that treat- ment with lytic phages can selectively attenuate the ethanol-induced liver disease caused by cytolysin-positive E. faecalis in humanized mice.",6,ALD patent background + target paper.pdf,157,True
498f1d8b3a437ae999e672b742edacb6,"Phage-based therapies have predominantly been studied in patients with bacterial infections in the gastrointestinal tract21–23, urinary tract24,25 and other organ systems26–28. The results of these studies— although mixed in terms of efficacy—strongly suggest that phage treat- ment offers a safe alternative to antibiotics26,27. However, safety studies are required for complex populations (such as patients with alcoholic hepatitis), because phages can induce a strong immune reaction29. Further",6,ALD patent background + target paper.pdf,159,True
a7f4dd56d870f83786e1ded97b09e6de,"work is required to determine whether phages that target cyto- lytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening disease that at present has no effective treatment. Eradication of this specific bacterial strain might produce better out- comes than current treatments, and environmental sources can be used to easily isolate phages that target cytolysin-positive E. faecalis. Here we provide an example of the efficacy of approaches based on phages in mice",6,ALD patent background + target paper.pdf,160,True
c04244d11660c52310810cb9c64c925b,"for a disease that is not considered a classic infectious disease. Our data also suggest that cytolysin may be used as a predictive biomarker of severe alcoholic hepatitis; an independent, prospective",6,ALD patent background + target paper.pdf,161,True
dc5e40d76e0eab42204f6a8153750a98,"7. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193–199 (1978).

8. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747–2756 (2008).

9. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).

10. Mathurin, P. & Lucey, M. R. Management of alcoholic hepatitis. J. Hepatol. 56, S39–S45 (2012).",6,ALD patent background + target paper.pdf,170,True
6ab480a65fa21c7c89c54c7f244a5b0c,"11. Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).",6,ALD patent background + target paper.pdf,171,True
58b63f2ac1b1120161190d90537f9369,No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.,8,ALD patent background + target paper.pdf,194,True
e042944def6cf71eb330b21b17b93bb3,"26 subjects without alcohol-use disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol-use disorder and 88 patients with alcoholic hepatitis. Patients with alcohol-use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption (self-reported >60 g/day) presented with various stages of liver disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index) (Supplementary Table 1). Patients with alcohol-use disorder",8,ALD patent background + target paper.pdf,196,True
c0ca7b327033c0e6165379376b8c68ba,"were recruited from an alcohol withdrawal unit in San Diego and Brussels, where they followed a detoxification and rehabilitation programme. At admission to the hospital, a complete medication and medical history was taken, and a complete physical examination was performed, including collection of bio-specimens, basic demographic data (such as age, gender, weight and height) and self-reported daily alcohol consumption. Patients were actively drink- ing until the day of admission. Controls or",8,ALD patent background + target paper.pdf,197,True
0f976c0e660004200f04da06431ab779,"Spain. Inclusion criteria for this study were active alcohol abuse (>50 g/day for men and >40 g/day for women) in the past 3 months, aspartate aminotransferase (AST) > ALT and total bilirubin >3 mg/dl in the past 3 months, and a liver biopsy and/or clinical picture consistent with alco- holic hepatitis. Exclusion criteria were autoimmune liver disease (ANA >1/320), chronic viral hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, pregnancy and a",8,ALD patent background + target paper.pdf,199,True
cd245ece245b24fa43712674060a852e,"lack of signed informed consent. In all patients, the clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology was consistent with the diagnosis of alco- holic hepatitis. Liver biopsies were only done if clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic hepatitis. Bio-specimens were collected during their admission to the hospital. The median time of specimen collection was 4 days fol- lowing",8,ALD patent background + target paper.pdf,200,True
38ce4f336a6096a4e0eb4efc385c6884,"admission to the hospital (range 0–24, n = 82). For one patient who underwent liver transplantation, the transplantation date was considered as date of death. Patients were censored at the time point at which they were last seen alive. The baseline characteristics are shown in Supplementary Tables 1, 2. Faecal 16S rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, ABIC score and discriminant function were calculated from all alcoholic hepatitis patients from whom",8,ALD patent background + target paper.pdf,201,True
8c2cd087d7482ec1cc860453e9de31fb,"Mice

C57BL/6 mice were purchased from Charles River and used in Fig. 2h and Extended Data Fig. 2. C57BL/6 germ-free mice were bred at UCSD and used in Figs. 2a–g, 3, 4, Extended Data Figs. 3, 7 and 9. Sublytic Atp4aSl/Sl",8,ALD patent background + target paper.pdf,204,True
0acac659a7a3f3c83930f1adf07c902d,"mice on a C57BL/6 background have previously been described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their wild-type littermates were used in Extended Data Fig. 5.",8,ALD patent background + target paper.pdf,206,True
db0feac9cc609c82c55d0c628caf10f8,"Female and male mice (age of 9–12 weeks) were placed on a chronic– binge ethanol diet (NIAAA model) as previously described15. Mice were fed with Lieber–DeCarli diet and the caloric intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in the early morning and killed 9 h later. Pair-fed control mice received a diet with an isocaloric substitution of dextrose.",8,ALD patent background + target paper.pdf,207,True
cb20161a2564d2d7216e477505fcbb8f,"Stool samples from patients with alcoholic hepatitis (Fig. 1) were used for faecal transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g stool dissolved in 30 ml Luria–Bertani (LB) medium containing 15% glycerol under anaerobic conditions), starting at an age of 5–6 weeks and repeated 2 weeks later. Two weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.",8,ALD patent background + target paper.pdf,208,True
8a6d17a0e3f64443f3390d86dca1c328,"In studies of the effects of cytolysin, 5 × 108 CFUs of a cytolytic E. fae- calis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2- 2(pAM771))5 (E. faecalis Δcytolysin) (kindly provided by M. S. Gilmore), or PBS (vehicle control) were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol feeding. Administration every third day was necessary, given that E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of phage",8,ALD patent background + target paper.pdf,209,True
f9d7bfe2eedac9500d5b3cdb1d356f97,"treat- ment, 1010 PFUs of E. faecalis phages (or C. crescentus phage phiCbK as control)35 were gavaged to the mice 1 day before the ethanol binge (at day 16). All animal studies were reviewed and approved by the Institu- tional Animal Care and Use Committee of UCSD.",8,ALD patent background + target paper.pdf,210,True
92ef1fa99dff370a9149c2961a1ed388,"The E. faecalis strain from Atp4aSl/Sl mice faeces has previously been isolated11 and was used to isolate phages Efmus1, Efmus2, Efmus3 and Efmus4 (phages specific to the E. faecalis strain isolated from mouse faeces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). E. faecalis strains from human stool samples were isolated using methods described below, and the cor- responding phages were named as Ef with patient number plus a digit (Ef for E.",8,ALD patent background + target paper.pdf,212,True
d3e8d3246d66c688354723e9dbcdf290,"E. faecalis phages were isolated from untreated raw sewage water obtained from North City Water Reclamation Plant in San Diego. Fifty millilitres of raw sewage water was centrifuged at 8,000g for 1 min at room temperature to pellet large particles. The supernatant was passed through a 0.45-μm and then a 0.2-μm syringe filter (Whatman, PES membrane). One hundred microlitres of the clarified sewage was mixed with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar)",8,ALD patent background + target paper.pdf,214,True
5a2ecb20b98679abe9ec4e7d4685525a,"and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, the resulting plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more times to ensure that the phages were clonal isolates.",8,ALD patent background + target paper.pdf,215,True
8aeb5a7c4f1f437cad055f2f2da16aae,"High-titre phage stocks were propagated by infecting 200 ml of expo- nentially growing E. faecalis at a multiplicity of infection of 0.1 in BHI broth containing 10 mM MgSO4. Lysis was allowed to proceed for up to six hours at 37 °C with shaking. The lysates were centrifuged at 10,000g for 20 min at room temperature to remove the remaining bacterial cells and debris. Supernatant was then vacuum-filtered through a 0.2-μm membrane filter and kept at 4 °C until use.",8,ALD patent background + target paper.pdf,216,True
b05d19fa5af188c7b8e5420e7cabc173,"Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF Concentrators with 100,000-molecular weight cutoff (MWCO) to a volume of approximately 1 ml. Following concen- tration, the culture medium was replaced with PBS via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml and adjusted to the required PFUs.",8,ALD patent background + target paper.pdf,217,True
a8bae4416c18abf2cac155e38c37d73a,"For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase and RNase at 37 °C for 1 h and phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4 °C overnight. Precipitated phages were then pel- leted by centrifugation at 10,000g for 10 min at 4 °C and resuspended in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA Clean-up kit (Promega). Phage genomes were",9,ALD patent background + target paper.pdf,219,True
59099ab5d3446bade1b274c1a33f5170,sequenced using a combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-based size selection before loading onto Illumina flow cells. Sequencing was performed with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) and loaded onto,9,ALD patent background + target paper.pdf,220,True
8bdbccea6236b8bbfd96fd480201388c,"MinION R9.4 flow cells. ONT reads were basecalled with Albacore v.2.3.4 (ONT). The sequence reads were demultiplexed and adapters trimmed from ONT reads using Porechop v.0.2.336. A hybrid Illumina-ONT de novo assembly was performed using the Unicycler v.0.4.7 pipeline37. Subsequently, Pilon v.1.2238 was used iteratively to polish the assemblies with Illumina reads until no addi- tional corrections could be made.",9,ALD patent background + target paper.pdf,221,True
ca35435b8ec55078f0a01c7a808831ea,"For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45-μm and 0.2-μm filters (VWR) and purified on a caesium chloride (CsCl) density gradient39. One millilitre of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qia- gen), amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a Bioruptor (Diagenode). Libraries were created using the Ion",9,ALD patent background + target paper.pdf,222,True
d2a1059394870487841ec6518e2f9ca7,"Plus fragment library kit and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 × coverage).",9,ALD patent background + target paper.pdf,223,True
1c53bab920a70926e09c18f7f7a39263,"Mapping of ONT reads to the hybrid assemblies was used to deter- mine the orientation and terminal ends of linear phage genomes, and reference genomes served as guides to orient circular phage genomes. Phage genome assemblies were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.",9,ALD patent background + target paper.pdf,224,True
91576a226a9cce9c84181d3e0cda5481,"Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3",9,ALD patent background + target paper.pdf,225,True
d23dd11e0d7d9d85c2aea1a91db70f28,"Genetic maps of phage genomes were generated by LinearDisplay. pl (https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://sourceforge.net/projects/mcj/) to render high- quality images. Preliminary annotation of genes was derived from the automated annotation and from Phage_Finder42, which uses curated hidden Markov models and databases of core phage gene to annotate core gene functions. Annotation was then manually reviewed to assign the final colours.",9,ALD patent background + target paper.pdf,227,True
a43d823c09b324b791bcb8beae797bac,"Phage phylogenetic tree

A phage whole-genome phylogeny tree was generated from a pairwise distance matrix calculated with the MASH program, which approxi- mates average nucleotide identity (ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated and sequenced in",9,ALD patent background + target paper.pdf,228,True
4e90311181576034039a159db8836df1,"this study plus 54 Enterococcus phage genomes obtained from Gen- Bank, with 5,000 12-mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial phage genome sequences to generate the ANI matrix using the mash distance command using default settings. The GGRaSP R package was used to calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI >99.985) were removed using the GGRaSP R package with a user",9,ALD patent background + target paper.pdf,229,True
006235dedb8b656ba8cae88658b1c5c8,"defined cutoff of 0.015 (ggrasp. cluster (threshold = 0.015)). The resulting dendrogram was translated into newick format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with taxonomic information and manually entered clade identification.",9,ALD patent background + target paper.pdf,230,True
26e716086b8135b36384ee83044eabb2,"DNA from human stool samples, mouse liver sections or bacterial cul- ture was extracted as previously described11, and DNA from mouse faeces was extracted using QIAamp Fast DNA Stool kit (Qiagen). 16S rRNA PCR was completed using Illumina adaptor and barcode-ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified using the Qiaquick PCR purification kit (Qiagen) using manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay",9,ALD patent background + target paper.pdf,233,True
702d4caabd5158cd933d728c9bc2cccf,"(Tecan), normalized and pooled in preparation for 16S rRNA sequencing. Pooled library was quantified and checked for qual- ity using Agilent 2100 Bioanalyzer (Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 cycles, 2 × 250-bp format using manufacturer’s specifications. 16S sequence reads were processed and operational taxonomic units were determined using our MOTHUR-based 16S rDNA analysis workflow as previously described11,49. Raw 16S",9,ALD patent background + target paper.pdf,234,True
ac97f219012f3111e9b6704302dea360,"Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and cylLL genes have previously been described50,51. All primers used in this study are listed in Supplementary Table 9. Mouse gene expression and amplification of bacterial genes were determined with Sybr Green",9,ALD patent background + target paper.pdf,237,True
bc267b0deb89a2c59e96f85c67de5eba,(Bio-Rad Laboratories) using ABI Ste- pOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 18S.,9,ALD patent background + target paper.pdf,238,True
a9f464facaa1cbf817a9c2422eaf8e4e,"To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial dilutions were made and 100 μl was placed on plates with selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the production of dark brown or black colour, generated by hydrolysis of esculin to esculetin (which reacts with ferric ammonium citrate). Each Enterococcus colony was then picked, and qPCR was performed to identify E.",9,ALD patent background + target paper.pdf,240,True
89cc95f4a0731b39a24a6b54c5a6ab46,"faecalis, using specific primers against the E. faecalis 16S rRNA gene50. For each subject, between 1 and 6 E. faecalis colonies were analysed and bacterial genomic DNA was then extracted as described in ‘Bacterial DNA extraction and 16S rRNA sequencing’.",9,ALD patent background + target paper.pdf,241,True
36cb8e6b2ee7ecc23a2b9f5175b6d079,DNA sequencing was performed on the Illumina HiSeq Ten X generat- ing paired-end reads (2 × 151 bp). Bacterial genomes were assembled,9,ALD patent background + target paper.pdf,242,True
099b7dfd205c297ccfd990d3aa6e41c5,"and annotated using the previously described pipeline52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes carried by E. faecalis isolates were identified by comparing individual genome assemblies against the CARD and VFDB databases, respectively, using abricate v0.8.10 (https://github.com/tseemann/abricate)53,54.",10,ALD patent background + target paper.pdf,244,True
4cd207c672357b22bc736d7265606756,"For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cutoff was used, and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this study have been deposited in the European",10,ALD patent background + target paper.pdf,245,True
160b9572e75fc7f21313c5b6fe72b406,"E. faecalis culture

All E. faecalis strains were grown statically in BHI broth or on BHI agar plate at 37 °C. Fifty micrograms per millilitre erythromycin was added when cytolytic and non-cytolytic E. faecalis strains were grown (Extended Data Fig. 2).",10,ALD patent background + target paper.pdf,247,True
0b3f87f0128253ff5d4a35973c23662d,"To determine levels of faecal enterococci in mice, 10–30 mg of mouse faeces was resuspended into 500 μl PBS and serial dilutions were made. Five microlitres of each dilution from each sample was spotted onto a plate with a selective medium, BBL enterococcosel broth (Becton Dickinson) and the plates were then incubated at 37 °C overnight. For Extended Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were identified by the production of a dark brown or black colour.",10,ALD patent background + target paper.pdf,249,True
6fbc1965b9031eac7d8fe0a1f15c0b0e,"To purify bioactive CylLL′′ and CylLS′′, an Escherichia coli heterologous expression system was used. In brief, either 6×His–CylLL or 6×His–CylLS were co-expressed with CylM (the enzyme that performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. The His tag and leader peptide were then removed using recombinant CylA (27–412), the soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive",10,ALD patent background + target paper.pdf,252,True
5aa1494873b653edbf3376e5eda334ee,CylLL′′ or CylLS′′. The resulting core peptides were further purified by reversed-phase high-performance liquid chromatography (HPLC).,10,ALD patent background + target paper.pdf,253,True
b31c744b5081aaac404dd88ef2fddd09,"The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 backbone vector that contained the cylM gene in MCSII6. The cylA (27–412) gene was previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star (DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, cylLS_cylM:pRSFDuet or cylA (27–412):pRSFDuet plasmids via KCM chemical transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 μg/ml) and",10,ALD patent background + target paper.pdf,254,True
409aae3f1eba8cc017c19167bc703e6f,grown at 37 °C overnight. One colony was picked to inoculate 15 ml of LB broth supplemented with kanamycin overnight at 37 °C. The culture was used to inoculate 1.5 l of terrific broth supple- mented with kanamycin. Cultures were grown with shaking at 37 °C to an optical density at 600 nm (OD600) of 0.8. The temperature of the incu- bator was lowered to 18 °C and expression was induced with the addi- tion of 0.3 mM final concentration of isopropyl β-d-thiogalactoside. The cultures were allowed,10,ALD patent background + target paper.pdf,255,True
8e5b87a0a6d982b36d840a001ad89e9e,"to incubate at 18 °C for 18 h. The cells were collected by centrifugation at 5,000g for 12 min. The cell paste was collected and frozen at -70 °C.",10,ALD patent background + target paper.pdf,256,True
95b7fab4c3c4954353259b85595a6288,"For the purification of the protease CylA (27–412), the cell paste was thawed and resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension was lysed by homogenization. The lysate was clarified by centrifugation at 13,000g for 45 min and filtered through a 0.45-μm centrifugal filter (Thermo Scientific). The clarified",10,ALD patent background + target paper.pdf,257,True
34a8543d6f0ed82dc1b09027480afb04,"lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a peristaltic pump. The loaded column was con- nected to an ÄKTA pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as determined by 4–20% SDS–PAGE, were combined, concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into",10,ALD patent background + target paper.pdf,258,True
caeefdcf1084e77ff5e6857cc445e3ff,"storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). Protein concentration was determined by absorbance at 280 nm.",10,ALD patent background + target paper.pdf,259,True
dca8b89b3f4eba96883fe6595de92729,"For the purification of CylLL′′ and CylLS′′ peptides, the cell paste was thawed and resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2-s pulse on, 5-s pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation at 13,000g for 45 min. The clarified cell lysate was filtered through a 0.45-μm centrifugal filter and applied via gravity flow to a pre-equili-",10,ALD patent background + target paper.pdf,260,True
c0fe84d533b3c2dc3baec429d45bd71d,"brated, 2 ml bed volume of His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The peptides were eluted with 10 ml of LanA elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final",10,ALD patent background + target paper.pdf,261,True
c5c35ee95bdcc35de798b9a11aa9ed68,concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.,10,ALD patent background + target paper.pdf,262,True
e23a4d1755011379bc6eca0c3bce3bfa,"The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. The solution was centrifuged at 4,500g for 10 min and filtered through a 0.45-μm syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse-phase HPLC using a Phenomenex Jupiter Proteo column (10 mm × 250 mm, 4 μm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were separated using a linear gradient of 3% (v/v) solvent B",10,ALD patent background + target paper.pdf,263,True
e7b6e4f32f22069121b573fc9ad95185,"(acetonitrile + 0.1% trifluoroacetic acid) in solvent A (water + 0.1% trif- luoroacetic acid). The fractions were spotted on a matrix-assisted laser desorption/ionization (MALDI) target plate by mixing 1 μl of sample with 1 μl of a 25 mg/ml solution of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were analysed by MALDI–time of flight (TOF) mass spectrometry on a Bruker UltrafleXtreme MALDI–TOF/ TOF operating in positive ionization, reflector mode.",10,ALD patent background + target paper.pdf,264,True
3a9f17d58ca5c1ed985aa20b6572a3e5,Hepatocytes were isolated from C57BL/6 female mice fed the chronic– binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced and filtered using a 70-μm nylon cell strainer. Hepatocytes were centrifuged at 50g for 1 min after 3 washes. Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher,10,ALD patent background + target paper.pdf,266,True
5507af1caa99c80bdb1e3ffd8d38a71b,"Scientific). Hepatocytes (1.5 × 105) were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin–transferrin–selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics. After 4 h, the culture was washed with DMEM-F12 medium and changed to the same complemented medium without FBS58. Then 16 h later, hepato- cytes were cultured with",10,ALD patent background + target paper.pdf,267,True
a7c38a89a8698c16dd863b474932e67e,Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride,10,ALD patent background + target paper.pdf,270,True
d49b5f36c647dff9812e57563fc16120,"Formalin-fixed tissue samples were embedded in paraffin and stained with H & E. To determine lipid accumulation, liver sections were embed- ded in OCT compound. Eight-micrometre frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). Representative images from each group of mice are shown in each figure. The terminal deoxynucleo- tide transferase-mediated dUTP nick-end labelling (TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly",11,ALD patent background + target paper.pdf,273,True
266821d571654b9cf819491e7ad4f506,"Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and multivariate Cox regression analysis was used to detect associations of cytolysin with overall mortality. The multivariate model was adjusted for geographical origin of the patients, antibiotic treat- ment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. Univariate logistic regression analysis of laboratory and clinical parameters associated with the detection of cytolysin and",11,ALD patent background + target paper.pdf,276,True
49a403ab85cf1287247d0dee3c6104d2,"E. faecalis was performed. Univariate linear regression analysis of labo- ratory and clinical parameters associated with the log-transformed total amount of faecal E. faecalis measured with qPCR was performed. To associate log-transformed total E. faecalis and E. faecalis positiv- ity with mortality, univariate Cox regression was used. P values from univariate and multivariate Cox regression, univariate logistic regres- sion and univariate linear regression were determined by Wald test.",11,ALD patent background + target paper.pdf,277,True
8d804e9fc95ed2db69557c927cb77778,"Multicollinearity was examined using the variance inflation factor. Kaplan–Meier curves were used to compare survival between cytolysin- positive and cytolysin-negative patients with alcoholic hepatitis. Faecal E. faecalis, bacterial diversity and richness from controls and patients were compared using Kruskal–Wallis test with Dunn’s post hoc test. Region- and/or centre-specific clinical characteristics of patients with alcoholic hepatitis were compared with Kruskal–Wallis test for continu- ous",11,ALD patent background + target paper.pdf,278,True
7b8dbc9af15bbcc3e361831b11ca9cb8,"and Fisher’s exact test for categorical variables. Faecal E. faecalis in patients with alcoholic hepatitis with or without cytolysin, and with or without cirrhosis, were compared with Mann–Whitney-Wilcoxon rank-sum test. Faecal E. faecalis in patients with alcoholic hepatitis from different region and/or centres were compared with the Kruskal– Wallis test. The percentage of subjects with faecal samples that were positive for E. faecalis and cytolysin was compared using Fisher’s exact test,",11,ALD patent background + target paper.pdf,279,True
f76e2fd0575907e2393cf2e9bac23226,"followed by FDR procedures for multiple group comparisons. Jaccard dissimilarity matrices were used for PCoA, and P values were determined by PERMANOVA followed by FDR procedures to correct for multiple comparisons.",11,ALD patent background + target paper.pdf,280,True
14e86a0ecd10b0bdc033d9707701e4ea,"For mouse and cell culture studies, the significance of multiple groups was evaluated using one-way or two-way ANOVA with Tukey’s post hoc test. Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for multiple comparisons. Kaplan–Meier curves were used to compare survival between experi- mental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed between experimental mouse groups and the P values were determined by PERMANOVA",11,ALD patent background + target paper.pdf,281,True
32c2ea73902ed3c942e714bd6eee2331,"Exact P values for all comparisons, together with group size for each group, were listed in Supplementary Table 10. Statistical analyses were performed using R statistical software, R v.3.5.1 (R Foundation for Sta- tistical Computing) and GraphPad Prism v.6.01. A value of P < 0.05 was considered to be statistically significant (adjusted for multiple comparisons when performing multiple tests).",11,ALD patent background + target paper.pdf,283,True
1bea2d99c1de3a43e7eef19cff96d941,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSa- mple identifiers (SAMN11089809–SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at the ENA under study PRJEB25007.,11,ALD patent background + target paper.pdf,287,True
5394a8c018c88ac0536804b7b2d6477f,"34. Krieg, L. et al. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood 118, 6418–6425 (2011).",11,ALD patent background + target paper.pdf,292,True
3f17dba3585624b45708b6cdb2c1a58d,"44. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

45. Letunic, I. & Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242–W245 (2016).",11,ALD patent background + target paper.pdf,298,True
f4bb22faef5daa08533bf8dfbc9d210b,"49. Chen, P. et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203–214.e16 (2015).",11,ALD patent background + target paper.pdf,301,True
f124b103101de64fc996b147c774e243,"57. Tang, W., Bobeica, S. C., Wang, L. & van der Donk, W. A. CylA is a sequence-specific protease involved in toxin biosynthesis. J. Ind. Microbiol. Biotechnol. 46, 537–549 (2019).",12,ALD patent background + target paper.pdf,308,True
185b9ea67d68e949dd1a9b4978ad85c7,"analysis and interpretation of data and key preliminary experiments; S. Lang, K.B., J.L. and X.M.T. provided assistance with statistical analysis; H.C., L.J., B.G., W.S., R.K., F.H. and S. Lee provided assistance with data acquisition; R.C.W., T.H.C., K.N., M.T. and D.E.F. were responsible for 16S rRNA sequencing, phage genome sequencing and data analysis; Y.S. and T.D.L. were responsible for bacterial genome sequencing and data analysis; A.H.-M., L.L. and R.Y. provided assistance with phage",12,ALD patent background + target paper.pdf,314,True
46c705e16cd763c9771436ac18f81264,[ - 00 Bacterial Genera Bacteroides Unclassified Lachnospiraceae Unclassified Ruminococcaceae 80 Veelllonella Akkermansia 70 Prevotella Blautia 60 Rosebuna Escherichia/Shigella Streptococcus 50 Unclassified Clostndiales 40 Dialister Faecalibacterium Clostndium_XiVa 30 Ruminococcus Enterococcus 20 Megasphaera Mogamonas Ruminococcus2 Relative sequence abundance (%) 10 Bifidobacterium | | = B Q=) = = - B: B ... [remaining 309 | Alcoholic Controls AUD hepatitis,13,ALD patent background + target paper.pdf,322,True
13c2eda700daeea7cfac4eeb693fd871,"75). c, E. faecalis in faecal samples from controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. d, Percentage of faecal samples positive for E. faecalis in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. E. faecalis was detected in faeces from 80% of patients with alcoholic hepatitis, versus 36% of controls (P < 0.001). There was also a significant difference between",14,ALD patent background + target paper.pdf,368,True
c6c794005ed2c243b6b65bc3dfd034cf,"or cytolysin-negative (n = 54), assessed by qPCR (P = 0.8174). g, 16S rRNA sequencing of faecal samples from patients with alcoholic hepatitis from different centres (France, n = 9; Mexico, n = 6; Spain, n = 5; UK, n = 11; USA (east), n = 16; USA (Midwest), n = 12; USA (west), n = 16 patients). We used PCoA based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between patients from different",14,ALD patent background + target paper.pdf,370,True
04f8e25335c7c097cf73a9f4a4bbef35,"regions (P < 0.01). h, Percentage of faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin- positive), in patients with alcoholic hepatitis from different centres (France,",14,ALD patent background + target paper.pdf,371,True
110198f4cecac26794a2b9b07553eeb2,"positive for E. faecalis in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.2878). Results are expressed as mean ± s.e.m. (c, f, i, l). For the box and whisker plots in b, the box extends from the 25th to 75th percentiles, and the centre line represents the median; for all three groups, the bottom whiskers show the minimum values; for the control group (black), the top whisker shows the maximum value; for the other two groups, the top",14,ALD patent background + target paper.pdf,374,True
fce98a9079b5963ef312b9f85de722b8,"whiskers represent the 75th percentile plus 1.5× the inter-quartile distance (the distance between the 25th and 75th percentiles); all values greater than this are plotted as individual dots. P values were determined by Kruskal– Wallis test (i) with Dunn’s post hoc test (b, c), two-sided Fisher’s exact test (h, j, k, m) followed by FDR procedures (d), two-sided Mann–Whitney Wilcoxon rank-sum test (f, l) or PERMANOVA (g). The exact group size (n) and P values for each comparison are listed in",14,ALD patent background + target paper.pdf,375,True
550684485674072abafcf4f167f8b82d,"lipopolysaccharide (LPS) by enzyme-linked immunosorbent assays. l, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices showed no significant differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following",16,ALD patent background + target paper.pdf,396,True
064f217c6f689fd99666e16faa4d30e3,"feeding with the control and ethanol diets. Compared to mice fed with a control diet, mice fed with an ethanol diet had significantly different faecal microbiomes after gavaging with E. faecalis (P < 0.05). m, n, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis after ethanol feeding. o, Mice were gavaged with cytolytic or non- cytolytic E. faecalis strains (carrying the",16,ALD patent background + target paper.pdf,397,True
f3de804e37dd92a77be6a081d904b203,"erythromycin resistance gene; 5 × 108 CFUs) at time 0, and faeces were collected 0, 8, 24, 48 and 72 h later. Faecal CFUs of Enterococcus were determined by culturing faecal samples on BBL enterococcosel broth agar plate with 50 μg ml-1 erythromycin. At time 0 and 72 h, five out of five and four out of five mice, respectively, had no detectable erythromycin-resistant Enterococcus in their faeces. These points are not shown on the graph, but have been included in the calculation of mean ± s.e.m.",16,ALD patent background + target paper.pdf,398,True
66a5c17e414f00a8c6cbd4f18aef4db9,"TUNEL AH cytolysin positive #1 r AH cytolysin positive #2 AH cytolysin negative #3 [N AH cytolysin negative #4 Percent positive (%) i il l 1l Control Ethanol

R Control . 3 /3% ¥ Ethanol F R o Ve, AH cytolysin AH cytolysin AH cytolysin AH cytolysin positive #1 positive #2 negative #3 negative #4

Cxcl2 Fold change - o oo 3 i Control Ethanol

Acta2 10 Fold change Control Ethanol",17,ALD patent background + target paper.pdf,401,True
ff9d64831d16a0ded96ff2e6dbab66ca,"colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, following the control diet. Mice transplanted with faeces from a cytolysin-positive patient with alcoholic hepatitis (patient",17,ALD patent background + target paper.pdf,408,True
8a092a9fc4f0f2e603dc4aec6e5ebda3,"no. 2) showed a microbiota that was significantly different to that of the other mouse groups following ethanol administration (P < 0.01). g, Percentage of cytolysin-positive E. faecalis in four patients with alcoholic hepatitis. Stool samples from the four patients were placed on plates with selective medium, and Enterococcus colonies were identified by the production of a dark brown or black colour. Enterococcus colonies were confirmed to be E. faecalis by qPCR. The cytolysin status of each E.",17,ALD patent background + target paper.pdf,410,True
4a5bb1e756991a1edd43066e311c2280,"results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001.",17,ALD patent background + target paper.pdf,412,True
7685edd1a6f2798486848d3a1a0c112f,"a Head s v % | . 2 | % o . Tail Siphophage Myophage Podophage (long, flexible, (contractile tail) (short, noncontractile tail) noncontractile tail) S5 or ¥ @ ¥ % Efmus1 Efmus2 Efmus3 Efm us4 Efmus1 (17,927 bp) y b Efmus2 (18,366 bp) Efmus3 (18,286 bp) T SN Efmus4 (18,186 bp) D ol | encapsidation/terminase [ tail fiber DNA polymerase | [l endolysin/lysin | I hypothetical protein - major capsid [ tail components [ DNA binding intron/intein [ holin Il ortal",18,ALD patent background + target paper.pdf,414,True
07050f0ff43493f216963888170f3067,"Serum ALT 500 — 400 ~300 200 - 100 ll WT II WT Atpas Control Ethanol

Hepatic triglycerides PBS C. crescentus phages 60 E. faecalis phages PBS C. crescentus phages EEEE E. faecalis phages '. i WT WT I/I Control Ethanol

S =y 5 Control "" | ey 3 - 3 Ethanol > R - 2 e PBS C. crescentus phages E. faecalis phages PBS C. crescentus phages E. faecalis phages WT Atp4ass

Cxcl1 15 es — e, 10 .- ""~ Fold change - o M | i WT WT /I Control Ethanol",19,ALD patent background + target paper.pdf,424,True
cfd6f71d41302ad17e0349d23f3478de,"Cxcl2 pes 3 — i - o - =3 Fold change ] . H - _ B L & WT I/ WT Control Ethanol

Liver cylLg 100 — s i 8 3 ] Percent mice (%) 8 2 nd o 3 /I WT / Control Ethanol

b S — e - o - o Fold change 5 SUs WT Atpda WT A Control Ethanol

Fecal Enterococcus 1010 10° 2108 108 10% il | 104 WT / WT / Control Ethanol

PBS a C. crescentus phages o8 E. faecalis phages o o & > Control PBS (10.08%) ] C. crescentus phages Atpdassi PC2 E. faecalis phages -1.0 4 17.1) 0",19,ALD patent background + target paper.pdf,425,True
97eea067db56287109cd9915c89a6f7c,"procedures (g) or PERMANOVA followed by FDR procedures (i). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",20,ALD patent background + target paper.pdf,447,True
d9d851e2342951de959914430e46830b,"Ef5.1 F)- ) ) o l ) ) o (41,141 bp) Ef5.2 (41,418 bp) ) b o s i D Ef5.3 F)- b ) o ol e ) ) (39,115 bp) Ef5.4 (41,141 bp) W) e om Ef2.1 (140,938 bp) PP o ) ) s o ) ) o D DO O OO 0 0 ¢ Ef2.2 ( W W (58,400 bp) L Ef2.3 i oo ) ) o (147,289 bp) ) ) m) m) o m m Capsid structural components Tail and baseplate and assembly assembly [ encapsidation/terminase [ tail fibers - DNA polymerase - endolysin/lysin - hypothetical protein (] major capsid - tail component [ DNA binding I holin intron/intein I rortal",21,ALD patent background + target paper.pdf,451,True
5e65bb528a0462abbeb41d6fda397cb8,"collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices shows no significant differences in the faecal microbiota of mice gavaged with control phage and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c–e, g, h). P values were determined by two-way",22,ALD patent background + target paper.pdf,463,True
3dcba7887dc4bafcba4fee83e5039e68,"ANOVA with Tukey’s post hoc test (a, c–e, g, h) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, ***P < 0.001.",22,ALD patent background + target paper.pdf,464,True
36746146626a68c1869d333cae1ffd69,"Ef6.1 ) b e o 4 (40,429 bp) Ef6.2 (17,966 bp) ) o Ef6.3 ) o (18,136 bp) Ef6.4 s ) o (41,133 bp) Ef7.1 D ) | (58,018 bp) - Ef7.2 1 ) o s (18,737 bp) Ef7.3 oo (18,818 bp) Ef7.4 (18,415 bp) C apsid structural components Other N and assembly || encapsidation/terminase [ tail fibers - DNA polymerase [ endolysin/ysin | [ hypothetical protein - tail component I intron/intein major capsid [ DNA binding [ holin I portal [ tail measure [ regulatory DNA recombination [l protease (scaffold protein) I",23,ALD patent background + target paper.pdf,466,True
045bb667bb02c256e39972e6453647d8,from GenBank (denoted by black letters) and 19 were from this study (4 phages against cytolysin-positive E. faecalis isolated from mice (shown in blue letters); 7 phages against cytolysin-positive E. faecalis isolated from patients with alcoholic hepatitis (shown in pink letters); and 8 phages against cytolysin- negative E. faecalis isolated from patients with alcoholic hepatitis (shown in green letters)) with Mash43 using a sketch size of s = 5000 and a k-mer size of k = 12 and GGRaSP59,24,ALD patent background + target paper.pdf,472,True
3339a5608a94dffc480710212d1278bb,"Control 1.0 C. crescentus phages g Cytolysin-positive E. faecalis phages | Patient #6 2 C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #7 g ] PC2 (19.54%) -0.5 -1.0 -1.0 1.0 PC1

Ethanol . - C. crescentus phages Cytolysin-positive E. faecalis phages Patient #6 0. C. crescentus phages u|| Cytolysin-positive E. faecalis phages Patient #7 0.0 PC2 (15.2%) -0.3 -0.2 0.2 0.50 (.)

Serum ethanol 1,000 800 (1] 600 I (mg/dl) 400 200 Patient Patient #6 #7 Ethanol",25,ALD patent background + target paper.pdf,479,True
e082f2210f85b74bb74f09ffc7ad7d30,"Extended Data Fig. 9 | Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages targeting non-cytolytic E. faecalis (1010 PFUs),",25,ALD patent background + target paper.pdf,481,True
1d7af732e5a50753c3d4a4b86ee5665e,"genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant difference in faecal microbiota among mice gavaged with control phages and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, g, h). P values were determined by two-way ANOVA with Tukey’s post",25,ALD patent background + target paper.pdf,484,True
a59fceee82250b70b476ce79598c3840,"For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described",26,ALD patent background + target paper.pdf,490,True
7283176899e9359a7761c62c0e8578cd,"solely by name; describe more complex techniques in the Methods section. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis",26,ALD patent background + target paper.pdf,491,True
744b1ea1b50d5157015a0ccb020f44ff,"testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated",26,ALD patent background + target paper.pdf,492,True
59cb227458d0170c095d9a964b471e9c,"Bacteriophage sequencing and phage tree: Albacore v2.3.4 (ONT), Porechop v0.2.3, Unicycler v0.4.7 pipeline, Pilon v1.22, CLC Genomics Workbench 4.9, NCBI Prokaryotic Genome Annotation Pipeline, in-house PERL script using Xfig, Phage_Finder, MASH program, GGRaSP and APE R-package, iTOL tree viewer 16S sequencing: MOTHUR-based 16S rDNA analysis workflow E. faecalis genome sequencing and tree: abricate v0.8.10 , Prokka, Roary, RAXML, iTOL Statistical analyses: R",26,ALD patent background + target paper.pdf,497,True
db919547ce2b2fb8114099bdb5949cb6,"For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",26,ALD patent background + target paper.pdf,499,True
02eed19603761eb3a5a1bfcd12f13125,"All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets",26,ALD patent background + target paper.pdf,501,True
a45bda3b81483a87565a5c5d14f72869,available at NCBI under the following consecutive BioSample IDs (SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at ENA under Study PRJEB25007.,27,ALD patent background + target paper.pdf,509,True
1782d002a5db530f4f0491d834b12409,"Sample size No power analyses or other calculations were used to predetermine sample sizes. Sample sizes were chosen based on prior literature using similar experimental paradigms (Nat Commun. 2017;8:2137; Gut. 2019;68:1504-1515) Data exclusions No data were excluded Replication In vivo experiments: more than two technical replicates (from different cohorts, on different dates), as well as biological replicates were performed to ensure data reproducibility; In vitro experiments: three",27,ALD patent background + target paper.pdf,514,True
31287eec58409495d16539420bfe7d0f,independent experiments and also replicates were performed on different dates to ensure data reproducibility. All replications were successful. Randomization Mice of similar age and weight were randomly assigned to experimental and control groups. Blinding The investigators were not blinded during cell and animal experiment assays.,27,ALD patent background + target paper.pdf,515,True
2a5b0b192987cbbcb213e79f0f5b91fc,"Ethics oversight All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.",27,ALD patent background + target paper.pdf,520,True
60bb3c1268359bab70329f41a916b08e,"Patients with alcohol use disorder fulfilling the DSM IV criteria (J Abnorm Psychol. 1997;106:545-553) were recruited from an alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a detoxification and rehabilitation program. Alcoholic hepatitis patients were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers in the USA, Mexico, United Kingdom, France and Spain. Detailed inclusion and",28,ALD patent background + target paper.pdf,527,True
9f978083d35ae2daa32d7ef55673dd5b,"The protocol was approved by the Ethics Committee of Hopital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San Diego",28,ALD patent background + target paper.pdf,530,True
3dff5bf0dd3d987610c819245891f764,"Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and",1,GvHD-paper.pdf,539,True
aaa0885b0f55e841fb07099e59cf25f8,"exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.",1,GvHD-paper.pdf,540,True
43c6d0fc9904d9d1a853af41520f416c,"are impor- tant causes of multidrug-resistant infections in patients (4). In single-center studies, E. faecium has been observed to dominate the fecal microbiota of immunocompromised patients after allogeneic hematopoietic cell transplantation (allo-HCT), a curative-intent therapy for hematological malignancies (5–7). Moreover, fecal domination with vancomycin- resistant enterococci increases the risk of",1,GvHD-paper.pdf,542,True
1b22244d9546e48c7c6e6d5783287762,"bloodstream infection in allo-HCT patients (5, 8). Patients with severe graft-versus-host disease (GVHD) after allo-HCT have poor outcomes with only ~30% long-term survival (9). Gut microbiota perturbations caused by broad-spectrum antibiotics and a reduction in microbial diversity are associated with in- creased transplant-related mortality and lethal GVHD in humans and mice (10–13). Besides causing infections, experimental studies in gno- tobiotic mice have revealed that enterococci play an",1,GvHD-paper.pdf,543,True
f61465198e6440e5f43238f30249cc80,"important role in colitis (14) by stimulat- ing antigen-presenting cells and CD4+RORg+ T cell infiltration, causing intestinal inflam- mation (15). In this study, we investigated the role of enterococci in the development of acute GVHD, both in allo-HCT patients and preclinical allo-HCT mouse models.",1,GvHD-paper.pdf,544,True
e4f3a612c5044eda5f3f1695a85bc930,We used 16S ribosomal RNA (rRNA) gene sequencing to study the fecal microbiota of 1325 adult allo-HCT recipients at four HCT centers: Memorial Sloan Kettering Cancer,1,GvHD-paper.pdf,545,True
b59c3859e6f00b6fade6679a559fc46d,"Center (MSKCC) (United States), Duke Uni- versity (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). Patient characteristics are shown in table S1. We observed high abundance of enterococci soon after transplantation in samples from all four transplant centers (Fig. 1B and fig. S1B). We defined Enterococcus domination as relative genus abundance ≥0.3 (≥30%) in any fecal sample, following a thresh- old we have used previously (5) (materials and methods and",1,GvHD-paper.pdf,546,True
ba5a7cd89a0dd0e1e025134ac812d2fa,"fig. S2C). The incidence of domination rose comparably across cen- ters, with up to 65% of patients exhibiting a domination event after allo-HCT (Fig. 1A). E. faecium was the dominant species in both the MSKCC and the multicenter-validation cohort (Duke, Hokkaido, and Regensburg) (Fig. 1B, fig. S1, and table S2), where 40.1% of MSKCC patients (441 of 1101 patients) and 46.0% of multicenter-validation patients (103 of 224 patients) met criteria for domination at any time point between day −20 and",1,GvHD-paper.pdf,547,True
07dfeaf72aaa01606b402fc242d17978,"early posttransplant period (day 0 to +21) was associated with significantly reduced overall survival and increased GVHD-related mortality in both the MSKCC and multicenter- validation cohort, as well as an increased risk of moderate-to-severe acute GVHD in the MSKCC cohort (Fig. 1, C and D, fig. S2, A and B, and table S3). The risk of relapse or disease progression was not associated with enterococcal domination in either cohort. The association of domination by genus Enterococcus with clinical",1,GvHD-paper.pdf,549,True
0b3f9ba03bbc4a8ad978c5a6129cefeb,"outcomes in the MSKCC cohort remained significant in a multivariate analysis adjusted for graft source, disease, conditioning intensity, gender, and age (table S4). In a subset of MSKCC patients, the vanA operon was found in 152 (37.4%) of 406 patients that had samples available for analysis, indicating the presence of vancomycin-resistant enterococci (VRE) (fig. S2E). Notably, expansions of several different taxa were detected in fecal samples in this study, but the Enterococcus genus was the",1,GvHD-paper.pdf,550,True
7167bbe87dc96d8199e21579ac3e08d9,"To further investigate these clinical obser- vations, we examined the fecal microbiota of mice early after transplantation using well- established mouse models of allo-HCT. In a major histocompatibility complex (MHC)– matched, minor-antigen-mismatched allo-HCT model [C57BL/6-to-129S1/Sv transplant (C57BL/ 6→129S1/Sv)], we performed 16S rRNA gene sequencing of fecal samples and found that E. faecalis dominated the fecal microbiota at posttransplant day +8 in mice who re- ceived T cell–replete",2,GvHD-paper.pdf,561,True
43839c87eb8aace015e7723f9fa7f14a,"grafts and developed lethal, acute GVHD (Fig. 2A and fig. S4A). In contrast to the patients who had pro- longed antibiotic exposures, this expansion of E. faecalis was independent of antibiotic administration and dependent upon GVHD, as it was not observed in control recipients of T cell–depleted allografts in which GVHD did",2,GvHD-paper.pdf,562,True
7684a55062ee8af4fdf8d0c77304a56f,"not develop. This posttransplant expansion of enterococci was consistently found in two additional lethal GVHD models: C57BL/6→ BALB/c mice (MHC-disparate model after ir- radiation conditioning) (Fig. 2B) and LP/ J→C57BL/6 mice [MHC-matched, minor- antigen–mismatched after busulfan and cyclophosphamide conditioning (16)] (Fig. 2C). The expansion of enterococci in murine allo- HCT recipients with GVHD was accompanied by an increase in Enterococcus colony–forming units recovered from mesenteric",2,GvHD-paper.pdf,563,True
aee0e1b81e7d3b79483c65310b022827,"Although we observed E. faecium domina- tion in patients and a transient expansion of E. faecalis in GVHD mice, we hypothesized that both members of this genus might be associated with GVHD. Of note, E. faecium",2,GvHD-paper.pdf,565,True
89027271151d4580fc1e3ab5a68f82c5,"only recently became recognized as a major human pathogen; before the 1990s it was E. faecalis that caused >90% of clinical in- fections (17). Because E. faecalis expands in mice with GVHD and is the major Enterococcus species in laboratory mice, we next investigated whether E. faecalis contributes to GVHD. We colonized germ-free C57BL/6 mice with a com- munity of six bacterial strains (Akkermansia muciniphila, Lactobacillus johnsonii, Blautia producta, Bacteroides sartorii, Clostridium bolteae,",2,GvHD-paper.pdf,566,True
0196242abc12beb7b4005908f58cc2d7,"and Parabacteroides diastonis; see materials and methods) (10, 18, 19) 21 days prior to allo-HCT (LP/J→gnotobiotic C57BL/6). One group of mice was cocolonized on day −21 with E. faecalis OG1RF, which remained detectable in mouse feces on days 0 and +7 (Fig. 2D, right panel, and fig. S4E). GVHD was exacerbated in E. faecalis–harboring mice",2,GvHD-paper.pdf,567,True
2e02651b2bf34489c2fbb4d5d62e9e86,E. faecium other E. spp. 1.00 E. faecium 0.60 E. cecorum M S E. durans 0.30 K C E. mundtii C 0.10 e c E. rivorum n a d E. moraviensis 0.01 n u E. gallinarum b a v 1.00 a E. lactis e l v i i d t E. malodoratus a a 0.60 l t e i r o E. ureasiticus n 0.30 c E. faecalis o h o 0.10 r t 0.01 20 60 80 −20 0 60 40 20 40 0 −20 80 day relative to HCT,2,GvHD-paper.pdf,573,True
d570fef3b0c8b7a841f6aa39ed31f5a9,Enterococcus domination of the gut microbiota [domination defined as a genus relative abundance of ≥0.3 (on a unitless scale from 0 to 1) over the course of allo-HCT (day −20 to +24 relative to HCT; using 7-day sliding windows) at different transplant centers]. (Right) Fraction of fecal specimens with enterococcal domination of the gut microbiota. (B) Relative abundance of different Enterococcus spp. in the microbiota of allo-HCT patients from the MSKCC and multicenter-validation cohort over the,2,GvHD-paper.pdf,577,True
9699d347d90b3ff6d6ed7bf145b4b245,"point represents a fecal sample, and color indicates the different Enterococcus spp.; the red dotted line indicates the threshold for domination set at a relative abundance ≥0.3. (C) Overall survival (left) and cumulative incidence of GVHD- related mortality (right) in the T cell replete graft recipients in the MSKCC patient cohort (see table S3), stratified into nondominated and Enterococcus- dominated groups (domination is defined as the relative genus abundance ≥0.3 in at least one sample",2,GvHD-paper.pdf,597,True
51c5aab43d05e63127bbe42b6cc4ad68,"BM+T 100 10"" ° 1 3x10* — BM (n=20) 102 107 2x10* — BM+T ® 50 102 10¢ g Enterococcus el.abundance 10+ A 19 o CFUs/g stool CFUs/mLN 1x10* 10° ° ) 10° o p<0.001 10 -1 4 7 10 10 7 10 0 5 10 15 20 days after HCT days after HCT days after HCT days after HCT c LP/J C57BL/6 16S rRNA feces Survival 14 days rel. to HCT o before bu/cy-cond 100 @ before HCT VVVYVYY v 1074 e BM ® BM+T — BM (n=9) AAA 1074 ¥ 50 g — BM+T (n=10) V busulfan g 'V cyclophosphamide Enterococcus rel. abundance 10° o 8 HCT p<0.01 10",3,GvHD-paper.pdf,607,True
6464d42cbded84d95353460653a01e18,"A allo HCTin AML patients == pre HCT/ non-dom. (i == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ Superpath. alanine biosyn. ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Calvin-Banson-Bassham cycld GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. Glycolysis IV P-diacylglycerol biosyn. | CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. N -2denosyl-L-methionine cycte | I",4,GvHD-paper.pdf,619,True
31cddea802aa517fb42fe13a7a3f3d9b,"A allo HCTin AML patients pre HCT (diverse) == pre HCT/ non-dom. (i M Enterococcus == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ B Akkermansia Superpath. alanine biosyn. W Blautia ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ W Clostridium Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Dorea Calvin-Banson-Bassham cycld Eubacterium GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. biosyn. ost HCT Glycolysis IV (E. F. domin.) I",4,GvHD-paper.pdf,621,True
851447f60b5755773ad526b4c7b664ba,F Clostridum vs. Enterococcus (genera) in allo-HCT patients Kendall tau =-0.21; p<0.001 1 3 o = 3 2 B o Clostridium 3 2 rel. abundance - 0 107 107 1 Enterococcus rel. abundance,4,GvHD-paper.pdf,637,True
2498ac75135d91cdb2352300d0b9073f,Kendall tau =-0.15; p = 0.008 20 0o butyrate mM oo 3 - orts o 0 107 10 _I- Enterococcus rel. abundance,4,GvHD-paper.pdf,651,True
cffa761b3293f1bad8dc1fd8805a8bb6,"vated and proliferating CD4+ T cells (fig. S4D; CD4+CD25+; CD4+Ki67+), and an increased number and percentage of CD4+RORg+ T helper 17 (TH17) cells in colon lamina propria (fig. S4D). Posttransplant administration of E. faecalis",5,GvHD-paper.pdf,658,True
dcee265dde1662d9b5135c2a51aa3aa4,"OG1RF to conventionally housed, T cell–replete bone marrow (BM+T)–transplanted BALB/c mice also aggravated GVHD (fig. S5A). These findings indicate that E. faecalis can aggravate GVHD severity.",5,GvHD-paper.pdf,664,True
0e59ef689baac0d6e83daed3d3dc10b2,"Statistical analysis of box plot data: *P < 0.05 (Wilcoxon rank test). (D) Cumulative incidence of acute GVHD grade 2 to 4 in rs4988235 SNP-genotyped MSKCC patients (T cell–depleted grafts excluded; graft source: BM/PBSC unmodified = 213 patients; cord blood = 102 patients; C/C = 175, T/C+T/T = 140). The cumulative incidence of grade 2 to 4 acute GVHD was compared between genotype groups using the R package cmprsk.",5,GvHD-paper.pdf,673,True
5a6c1e16a3e36906a3e2d3a8a327fc54,"We next considered whether posttransplant defects of mucosal defense mechanisms facil- itate enterococcal expansion. Immunoglobulin A (IgA) coating of intestinal bacteria can be protective in colitis and is important for maintaining mucosal integrity (20). How- ever, we did not observe members of the genus Enterococcus to be enriched in either IgA- negative or IgA-positive fecal fractions, even though total fecal IgA was significantly re- duced in allo-HCT recipients with GVHD (fig. S5, B to D).",6,GvHD-paper.pdf,689,True
d2fd496bdfe0b7e7b6ce33f463067ead,"Reduction of IgA by transplant- ing IgA-deficient bone marrow (BM) from activation-induced cytidine deaminase knock- out mice did not further increase enterococcal expansion (fig. S5E). Intestinal antimicrobial peptides of the Reg3 family can suppress the growth of VRE (21) and are reported to play a major role in GVHD (22). Accordingly, we found that both Reg3B/G transcripts and interleukin-22 protein, which regulates Reg3 expression (23), were reduced in the ileum of GVHD mice (fig. S5F).",6,GvHD-paper.pdf,690,True
f437430e0d1cd83772d368fde5605c8c,"Next, we analyzed microbiota-intrinsic fac- tors and used shotgun metagenomic sequenc- ing to characterize the metabolic potential of the Enterococcus-dominated fecal microbiota. Pre- and posttransplant fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia were selected for sequencing on the basis of having a highly diverse pre-HCT microbiota and posttrans- plant E. faecium domination (by 16S rRNA gene sequencing). We focused on microbial metabolic pathways that",6,GvHD-paper.pdf,691,True
954c9a9e57f11308dd3b33e7774937ff,"specifically charac- terize domination by comparing them with the highly diverse pretransplant microbiota from the same patients. Pathways involved in DNA synthesis and, notably, in lactose and galactose degradation were enriched in the E. faecium–dominated, posttransplant micro- biota. In contrast, amino acid synthesis and starch-degradation pathways were more prev- alent in pretransplant specimens (Fig. 3A). The lactose-and-galactose degradation path- way was also significantly enriched in the",6,GvHD-paper.pdf,692,True
1763b36f0e868d4f3f751a78c1fadc47,posttransplant E. faecalis–dominated samples of mice with GVHD (Fig. 3B). Comparison of whole-genome sequencing from isolates of E. faecium (from a human allo-HCT patient) and of E. faecalis (from a mouse with GVHD) revealed that genes encoding lactose and galactose metabolism accounted for ~3% of their genomes (Fig. 3C). In silico analysis of these Enterococcus genomes and publicly available genomes of other members of the gnotobiotic six-strain consortium revealed that enterococci are,6,GvHD-paper.pdf,693,True
5fb0585b5d598332dbfa0df06c2d09af,"specifically enriched in enzymes of the tagatose-type galactose path- way for galactose-to-glucose degradation (24) (materials and methods and fig. S6, A and B). Enterococcal growth depends on lactose in vitro, as both E. faecalis and E. faecium strains cultured in brain-heart",6,GvHD-paper.pdf,694,True
f40eea9163a0eafca1c765d2532619da,"infusion (BHI) broth depleted of lactose (by lactase; fig. S7A) did not grow (Fig. 3D). Growth was reinstated upon transfer to re- gular BHI, excluding antibacterial effects of lactase treatment (Fig. 3D). Enterococcal expansion after allo-HCT was accompanied by a loss of Clostridium spp. in the microbiota of allo-HCT patients (Fig. 3, A and F) and of mice with GVHD (fig. S8, A to C, and table S7). This may be important for allo-HCT patients, as high abundances of clostridia are associated with",6,GvHD-paper.pdf,696,True
83a84cf1c218335bbe5608707fd742dd,"better survival and low- er incidence of GVHD (12, 25). Commen- sal clostridia are known to produce large amounts of butyrate (26), which mitigates lethal GVHD in mice through protecting energy homeostasis of enterocytes (27). We observed that posttransplant enterococcal domination and a loss of clostridia were accompanied by a significant reduction in fecal butyrate in both allo-HCT patients and mice with GVHD (Fig. 3, E and G) (28). A loss of this key metabolite may contribute to the poor",6,GvHD-paper.pdf,697,True
b588c6e7e34cada90b753ddcecf6c937,"Given that the optimal growth of enterococci depends on lactose availability in vitro, we investigated whether enterococcal expansion can be mitigated by feeding mice lactose-free chow (fig. S7B and table S8). In the C57BL/ 6→BALB/c model, the absence of dietary lactose significantly reduced posttransplant Enterococcus bloom and mitigated GVHD (Fig. 4A and fig. S9B). Flow cytometric anal- ysis of donor T cells on day +14 revealed a reduction in the percentage of activated and proliferating CD4+",6,GvHD-paper.pdf,699,True
bbddbe11309e15be8746bc6e6d43c2f6,"T cells (CD4+CD69+; CD4+ Ki67+) as well as a reduction in the percent- age of CD4+Tbet+ (TH1) T cells (fig. S9). The effect of a lactose-free diet on enterococcal outgrowth and GVHD was replicated in the LP/J→C57BL/6 mouse model (Fig. 4B and table S9 for changes in non-enterococcal taxa). Intestinal mucosal damage by irradiation or allo-reactive T cells may affect the expres- sion of lactase, the enzyme found on small- intestine enterocytes that facilitates lactose absorption through",6,GvHD-paper.pdf,700,True
9580a38a6bd2010ce8455948bca92bea,"Next, we explored whether enterococci ex- pansion is associated with lactose tolerance in human allo-HCT patients by genotyping 602 patients from the MSKCC cohort with available pretransplant germline DNA sam- ples for the gene polymorphism rs4988235 (-13910*T). This single-nucleotide polymorphism (SNP) regulates lactase expression and pre- dicts lactose absorption and/or tolerance (C/T",6,GvHD-paper.pdf,702,True
e5a71d616a1f5fa0cabb719adc207bb7,"or T/T alleles) and malabsorption (C/C alleles) in the upper gut (29). Although abundance of the genus Enterococcus increased comparably during exposure to broad-spectrum antibiotics in both lactose absorbers and malabsorbers, enterococcal domination was significantly prolonged in malabsorbers after cessation of antibiotics (Fig. 4D and fig. S10). This finding suggests that the maintenance of enterococ- cal domination and microbiota recovery after broad-spectrum antibiotic exposure is signif-",6,GvHD-paper.pdf,704,True
b6a05d64d49450dd0c8ef03617fcb46d,"significant risk factor for the development of acute GVHD and for increased overall and GVHD-related mortality after allo-HCT. Our findings extend previous reports from smaller single-center analyses that posttransplant VRE bacteremia and fecal domination are associated with worse outcomes after allo-HCT (7, 8, 30). In gnotobiotic mouse models, enterococci exacerbate GVHD, consistent with previous reports of aggravated colitis in models of in- flammatory bowel disease (14) or systemic autoimmune",6,GvHD-paper.pdf,706,True
1c6bb1dfa8db30e79c638bec74376d1f,"responses (31). We previously identified Blautia abundance (a genus within class Clostridia) as a predictor of protection from lethal GVHD (12), whereas here we describe Enterococcus domination as a risk factor for GVHD. These two findings are noteworthy in light of our recent observa- tion that a B. producta strain can inhibit VRE growth via the production of a lantibiotic pro- tein (32). We identified a microbiota-intrinsic mechanism that is dependent on lactose uti- lization and favors the",6,GvHD-paper.pdf,707,True
cc33c91f1130a936ee46c6ae310e78a0,"expansion of enterococci. This process may be triggered through a loss of lactase produced by enterocytes damaged by conditioning or allo-reactive T cells. We validated this concept experimentally, by showing that depletion of lactose in vitro and in vivo inhibited enterococcal expan- sion and mitigated GVHD, and clinically, by showing that patients harboring a lactose- malabsorption allele experienced prolonged Enterococcus domination after antibiotic ex- posure. These observations in mice and",6,GvHD-paper.pdf,708,True
1871f55a7f0f2c529f132e462c348f1a,"Investigator Award/Gilead Sciences (N.K.); NIH KL2 TR001115-03 (NCATS CTSA to A.D.S.); NIA 2P30AG028716-11 (Claude D. Pepper Older Americans Independence Center to A.D.S.); NCI R01CA203950-01 (to N.J.C., A.D.S., L.B., M.L, and A.B.); NIH 1R01HL124112-01A (A.D.S. and R.R.J.); and NIA R21AG066388- 01 (A.D.S. and N.J.C.). Author contributions: C.K.S.-T., E.G.P., J.U.P, and M.R.M.v.d.B. conceptualized the project; C.K.S.-T., A.L.C.G., A.S., S.D., A.P., J.R.C., Y.T., R.R.J., J.B.X., E.R.L., and",7,GvHD-paper.pdf,725,True
098e8540f566a36f09c7ff336ae43224,"project and provided validation; and C.K.S.-T., J.U.P., A.L.C.G., and M.R.M.v.d.B. prepared data presentation and wrote the manuscript with contributions from all other authors. Competing interests: M.R.M.v.d.B has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia",7,GvHD-paper.pdf,728,True
3ce3922fd862b683589b6308cb40b131,"Ferring Pharmaceuticals; is an inventor on patent application number WPO2015179437A1, entitled “Methods and compositions for reducing Clostridium difficile infection,” and patent number WPO2017091753A1, entitled “Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization”; and holds patents that receive royalties from Seres Therapeutics Inc. Other authors have no competing interests. Data and materials availability: All data are available in the manuscript",7,GvHD-paper.pdf,730,True
95242abae2592d3655f378dd677c95b1,Lactose drives Enterococcus expansion to promote graft-versus-host disease,8,GvHD-paper.pdf,740,True
3a2aa0457adcaff586239378cb1d9d6e,"Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to",8,GvHD-paper.pdf,745,True
4b00abb7d1147c6075f334a2fe5f2f66,"provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models.",8,GvHD-paper.pdf,746,True
>>>>>>> 5b6e3e1f6bb904635df1f05e870b8aeeed94cf1b
